curriculum vitae and bibliography hugo e vargas, md...11/2016 re-aims 7/22/2020 3:25:34 pm hugo e...

Hugo E Vargas, MD

Curriculum Vitae and Bibliography

Present Academic Rank and PositionProfessor of Medicine - Mayo Clinic College of Medicine and Science 07/2006 - Present

Consultant - Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Phoenix/Scottsdale, Arizona

07/2014 - Present

Director for Research - Mayo Clinic Alix School of Medicine, Mayo Clinic College of Medicine and Science, Department of Education Administration, Scottsdale/Phoenix, Arizona

2016 - Present

Personal InformationPlace of Birth: Cúcuta, ColombiaCitizenship: United States of America

Work Address: Mayo Clinic5777 East Mayo BoulevardPhoenix, AZ 85054

Email Address: [email protected]

EducationUniversity of California, Davis - BS, Physiology 1982 - 1986

Hahnemann University Graduate School - Graduate School, M.S. Applied Human Physiology

1986 - 1989

Hahnemann University Graduate School of Medicine - MD, Doctor of Medicine 1987 - 1991

University of Utah Affiliated Hospitals - Internship, Internal Medicine 1991 - 1992

University of Utah Affiliated Hospitals - Resident, Internal Medicine 1992 - 1994

University of Pittsburgh Medical Center - Fellow, Gastroenterology and Hepatology

1994 - 1997

RE-AIMS 7/22/2020 3:25:34 PM

CertificationBoard Certifications

Academy of Pharmaceutical Physicians and Investigators

Physician Investigator 2009 - Present

American Board of Internal Medicine (ABIM)

Internal Medicine 1994 - Present

Gastroenterology 1997 - Present

Transplant Hepatology 2006 - Present

Maintenance of Certification (MOC) 2015 - Present

Association of Clinical Research Professionals

Certified Physician Investigator (CPI) 2009 - Present

Mayo Clinic Quality Academy

Mayo Clinic Quality Fellow: Bronze Level Certification 2011

Mayo Clinic Quality Fellow: Silver Level Certification 2016

LicensureUtah 187577-1205 (Medical) 1992 - Present

Pennsylvania Inactive (Medical) 1994 - 2006

Arizona 27561 (Medical) 1999 - Present

Minnesota 46140 (Medical) 2003 - Present

Nevada 10547 (Medical) 2003 - Present

Colorado DR.0054295 (Medical) 2014 - Present

RE-AIMS 7/22/2020 3:25:34 PM

Hugo E Vargas, MD of 67

Honors and AwardsHonors Award, Department of Physiology and Biophysics - Hahnemann University

1988

Summer Research Award - Hahnemann University 1988

Honors Award, Anatomy, Medicine, Ambulatory Care & Dermatology - Hahnemann University

1989

Chairman's Invitational Honors Program in Medicine - Hahnemann University 1990 - 1991

Outstanding Medical Resident of the Year - Department of Internal Medicine, University of Utah

1994

Young Investigator Award for the World Congress of Gastroenterology - American Association for the Study of Liver Diseases

1998

Academic Excellence Day Judge - Scottsdale, Arizona, Radiology Alumni Meeting, Mayo Clinic Alumni Association, Mayo Clinic College of Medicine

01/2003

Educator of the Year Award for Research - Mayo Clinic in Arizona, Mayo Clinic 2003

Outstanding Reviewer Award - American College of Gastroenterology 2004

Fellow - American College of Gastroenterology 2005 - Present

Fellow - American College of Physicians 2005 - Present

Fellow - American Gastroenterological Association 2006 - Present

Top 10 % Reviewer 2008 - Annals of Internal Medicine 03/2009

Outstanding Program Director of the Year - Mayo School of Continuous Professional Development, Mayo Clinic College of Medicine, Department of Education Administration

2010

AASLD Fellow - American Association for the Study of Liver Diseases 09/2014

Investigator of the Year - Mayo Clinic in Arizona, Mayo Clinic 2016

Fellow - American Society for Gastrointestinal Endoscopy 2019 - Present

RE-AIMS 7/22/2020 3:25:34 PM


Previous Professional Positions and Major AppointmentsMedical Consultant - Division of Social Security, State of Utah, Salt Lake City, Utah

1992 - 1993

Medical Consultant - Ambulatory Care Service, Veterans Administration Hospital, Salt Lake City, Utah

1994

PRN Physician - Mercy Hospital, Pittsburgh, Pennsylvania 1995 - 1997

Medical Consultant - Ambulatory Care Service, Veterans Administration Hospital, Pittsburgh, Pennsylvania

1996 - 1997

Assistant Professor of Clinical Medicine - Division of Gastroenterology, Hepatology, & Transplant Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

1997 - 1999

Assistant Professor Of Medicine - Division of Gastroenterology, Hepatology, & Transplant Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

1999 - 2000

Clinical Director of Hepatology - Division of Gastroenterology, Hepatology, & Transplant Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

1999 - 2000

Medical Director of Transplantation - Division of Gastroenterology, Hepatology, & Transplant Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

1999 - 2000

Senior Associate Consultant - Division of Gastroenterology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

2000 - 2001

Senior Associate Consultant - Division of Transplantation Medicine, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

2000 - 2001

Consultant - Division of Gastroenterology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

2001 - 06/2009

Consultant - Division of Transplantation Medicine, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

2001 - 06/2009

Associate Professor in Medicine - Mayo Clinic College of Medicine and Science 07/2001 - 06/2006

Chair - Hepatology, Division of Gastroenterology & Hepatology, Department of Internal Medicine, Mayo Clinic, Scottsdale/Phoenix, Arizona

2009 - 2014

Consultant - Division of Gastroenterology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

06/2009 - 07/2014

Consultant - Division of Hepatology, Department of Internal Medicine, Mayo Clinic, Scottsdale, Arizona

06/2009 - 07/2014

Vice Chair - Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Phoenix/Scottsdale, Arizona

07/2014 - 07/2015

Professional Memberships and Services

Academy of Pharmaceutical Physicians and InvestigatorsMember 2007 - Present

American Association for the Study of Liver Disease (AASLD)Global Outreach Committee

Professional Memberships and Societies

RE-AIMS 7/22/2020 3:25:34 PM


Member 2017 - Present

American Association for the Study of Liver DiseasesMember 1995 - PresentFellow 2014 - PresentAbstract Review Committee

Member 2003 - PresentChair 2006 - 2008

Annual Meeting Task ForceMember 2010

Associate Member CommitteeChairLiaison 2002 - 2004

Education CommitteeMember 2001 - PresentChair 2006 - 2008

Ethics CommitteeMember 2010 - 2013Chair 2014 - Present

HCV Guidance PanelMember 2014 - Present

Nurse Practitioner and Physician Assistant Selection CommitteeMember

American Board of Internal MedicineHepatology Exam Committee

Chairman 2018 - PresentTransplant Hepatology Test Writing Committee


American College of GastroenterologyMember 1995 - PresentFellow 2005 - Present

American College of PhysiciansMember 1991 - PresentFellow 2005 - Present

American Gastroenterological AssociationMember 1995 - PresentFellow 2006 - Present

American Society for Gastrointestinal EndoscopyMember 1995 - PresentFellow 2019 - Present

American Society of TransplantationMember 2002 - Present

American Transplant CongressAbstract Review Committee


RE-AIMS 7/22/2020 3:25:34 PM


Gastroenterologia LatinoamericanaInternational Editorial Board


International Liver Transplantation SocietyMember 1997 - PresentAbstract Review Committee

Member 2006

National Institutes of HealthInfectious, Reproductive, Asthma and Pulmonary (IRAP) Study Session

Ad Hoc Reviewer 02/2010National Institute of Diabetes and Digestive and Kidney Diseases

Ad Hoc Member 2003

Pennsylvania Society of GastroenterologyMember 1995 - 2001

University of Pittsburgh Medical CenterMedical Records Committee

Member 2000Pharmacy and Therapeutics Committee

Member 1998 - 2000

Journal Editorial Responsibilities

American Journal of GastroenterologyEditorial Board Member 2004 - PresentAssociate Editor 2016 - Present

Clinical Liver DiseaseSpecial Issue, Volume 14, Issue 3, September 2019

Guest Editor 09/2019

Digestive Disease and ScienceAssociate Editor 2001 - 2006

Gastroenterologia LatinoamericanaComite Editorial Internacional

International Board Member 2011 - Present

HepatologyEditorial Board Member 2017 - Present

Liver TransplantationAssociate Editor 2004 - 2006Senior Associate Editor 2006 - Present

World Journal of GastroenterologyEditorial Board Member 2005 - Present

Journal Responsibilities

RE-AIMS 7/22/2020 3:25:34 PM


Journal Other Responsibilities

American Journal of GastroenterologyJournal Referee

Annals of Internal MedicineReviewer

Digestive DiseasesJournal Referee

GastroenterologyReferee

Gastrointestinal EndoscopyJournal Referee

HepatologyJournal Referee

Liver InternationalJournal Referee

Liver TransplantationJournal Reviewer

Mayo Clinic ProceedingsJournal Referee

TransplantationManuscript Reviewer 03/2012

Education Interests and Accomplishments

Teaching

Portal Hypertension: Medical Grand RoundsEast Liverpool Medical CenterLiverpool, Ohio

Curriculum and Course Development

Update on Liver TransplantationCourse Co-DirectorMayo Clinic Arizona - CME Course

03/2005

Course DirectorGastroenterology and Hepatology Linked to Endoscopy: Mayo Clinic's 7th Annual Winter Course in ScottsdaleScottsdale, Arizona

02/2008

Keeping the Patient with End-stage Cirrhosis AliveCourse Co-Director: Postgraduate CourseAmerican Association for the Study of Liver DiseasesBoston, Massachusetts

10/2009 - 10/2009

Course Director19th Annual Mayo Clinic Internal Medicine Update: Sedona 2016Sedona, Arizona

10/2016

Emerging Trends SymposiumProgram ChairThe AASLD Liver MeetingBoston, Massachusetts

11/2016

RE-AIMS 7/22/2020 3:25:34 PM


PBL Sessions and Case WorkshopInstructor, Second Year Medical Course in GI

02/1995

PBL Sessions and Case WorkshopInstructor, Second Year Medical Course in GI

02/1996

Thomas E Starzl Transplantation InstituteContinuing Medical Education

05/1997

Portal HypertensionMedical Resident Core LectureMayo Clinic ArizonaScottsdale, Arizona

10/1997

Portal HypertensionMedical Resident Core Lecture (VAMC)United States of America

10/1997

PBL Session and Case WorkshopInstructor, 2nd Year Medical Course in GIUnited States of America

11/1997

PBL SessionInstructor, Second Rear Medical Course in GI

11/1997

Liver Function TestsLecture, 2nd Year Medical Course in GIUnited States of America

11/1997

Management of Hepatitis CMeadville Regional Medical CenterMeadville, Pennsylvania

02/1998

PBC/AIH OverlapChiefs Conference Medicine Housestaff

05/1998

GI Complications of PregnancyOB/GYN Resident Core Lecture (MWH)United States of America

05/1998

Portal Hypertension: Medical Grand RoundsUPMC JeanetteJeanette, Pennsylvania

07/1998

Portal HypertensionMedical Resident Core LectureUnited States of America

10/1998

Portal HypertensionMedical Resident Core Lecture (VAMC)United States of America

10/1998

TIPS and Surgical Shunts: Gut ClubBay State Medical CenterSpringfield, Maine

11/1998

PBL Sessions and Case WorkshopInstructor, Second Year Medical Course in GIUnited States of America

12/1998

Overview of Liver DiseasesLecture, 2nd year Medical Course in GIUnited States of America

12/1998

RE-AIMS 7/22/2020 3:25:34 PM


Interpretation of Lab TestsLecture, 2nd Year Medical Course in GIUnited States of America

12/1998

Ward Attending3rd Year Medical Students

02/1999

Overview of Liver Disease2nd Year Medical Course in GI

12/1999

PBL Sessions and Case Workshop2nd Year Medical Course in GI

12/1999

Interpretation of Lab TestsLecture, 2nd Year Medical Course in GI

12/1999

Hepatitis C Virus: It's Impact on the Health of Women, Obstetrics and Gynecology Grand RoundsMagee Women's HospitalPittsburgh, Pennsylvania

06/2000

Recurrent Viral Hepatitis after Liver Transplantation: What are our Strategies?Update in Liver Diseases and Transplantation 2001Mayo ClinicScottsdale, Arizona

03/2001

Management of Portal HypertensionFellowship training courseMayo Clinic ArizonaScottsdale, Arizona

07/2001

Hepatitis C for the InternistClinic Review SeriesMayo ClinicScottsdale, Arizona

03/2002

Spring Medical Publishing Seminar SeriesIn conjunction with the Section of Scientific Publications and Library ServicesMayo School of Continuing EducationScottsdale, Arizona

04/2002

Liver TransplantUpdate for the Primary Care PhysicianMayo Clinic GastroenterologyScottsdale, Arizona

06/2002

Update on the Management of Portal HypertensionMedical Grand RoundsMayo Clinic ScottsdaleScottsdale, Arizona

08/2002

Abdominal Liver EnzymesWinter Gastroenterology Meeting, Gastroenterology Linked to Endoscopy and Hepatology CourseMayo Clinic ScottsdaleScottsdale, Arizona

02/2003

Hepatitis C in Patients with Renal Disease: What's new in TreatmentUpdate in Liver Diseases and Transplantation CourseMayo Clinic ScottsdalePhoenix, Arizona

03/2003

RE-AIMS 7/22/2020 3:25:34 PM


Viral HepatitisUpdate in Liver Diseases and Transplantation CourseMayo Clinic ScottsdalePhoenix, Arizona

03/2003

Retransplantation for Hepatitis C in Era of Organ ShortageUpdate in Liver Diseases and Transplantation CourseMayo Clinic ScottsdalePhoenix, Arizona

03/2003

Spring Medical Publishing Seminar2nd in the Series, PanelistMayo Clinic ScottsdaleScottsdale, Arizona

04/2003

Update on HepatitisGrand Rounds PresentationPhoenix Indian Medical CenterPhoenix, Arizona

05/2003

Academic Excellence DayParticipation as a JudgeMayo Clinic ScottsdaleScottsdale, Arizona

05/2003

HBVMedical Resident LectureMayo Clinic ArizonaScottsdale, Arizona

2004

Management of Portal HypertensionMedical Resident LectureMayo Clinic ArizonaScottsdale, Arizona

2005

Management of Viral HepatitisMedical Resident LectureMayo Clinic ArizonaScottsdale, Arizona

03/21/2005

Ascites and Hepatorenal SyndromeResidents Noon ConferenceMayo Clinic ArizonaScottsdale, Arizona

2006

Ascites and Hepatorenal SyndromeResidents Noon ConferenceMayo Clinic ArizonaScottsdale, Arizona

2007

Management of the ESLD Patient Awaiting TransplantationInternal Medicine Noon Resident ConferenceMayo Clinic ArizonaPhoenix, Arizona

01/08/2009

Hepatitis C UpdateFamily Medicine Grand RoundsMayo Clinic ArizonaPhoenix, Arizona

09/05/2013

RE-AIMS 7/22/2020 3:25:34 PM


2014: The Year HCV Treatment Came of Age: Implications for the LT PopulationTransplant Grand RoundsMayo Clinic ArizonaPhoenix, Arizona

01/09/2014

Difficult to Treat Patients in 2014: OpportunitiesMedicine Grand RoundsUniversity of UtahSalt Lake City, Utah

02/2014

State of the art treatment for HCV:2017Annual Review of Gastroenterology HepatologyMayo Clinic Arizona Phoenix, Arizona

09/2017

RE-AIMS 7/22/2020 3:25:34 PM


Mentorship

Jatoi, Marshal (Research Fellow)Description: Current Status: Outcome:

Ahmad, Jawad (Clinical Fellow)Description: Current Status: Outcome:

Arenas, Juan (Research Fellow)Description: Current Status: Outcome:

Carey, Elizabeth (Clinical Fellow)Description: Current Status: Outcome:

Chopra, Kapil (Clinical Fellow)Description: Current Status: Outcome:

Fernando Gallegos, Juan (Research Fellow)Description: Current Status: Outcome:

Khatib, Amer (Clinical Fellow)Description: Current Status: Outcome:

Rodriguez-Luna, Hector (Clinical Fellow)Description: Current Status: Outcome:

Sass, David (Clinical Fellow)Description: Current Status: Outcome:

Sharma, Pratima (Clinical Fellow)Description: Current Status: Outcome:

Yusfi, Mahmoud (Clinical Fellow)Description: Current Status: Outcome:

Academic Career Development

Improving the Completion of Hepatitis A and Hepatitis B Vaccination Series Rates in Patients Listed for Liver Transplant: A Quality Improvement Project Mayo School of Continuous Professional DevelopmentPhoenix, Arizona

02/2016

RE-AIMS 7/22/2020 3:25:34 PM


Presentations ExtramuralNational or InternationalInvitedFor Your Health ProgramMayo Clinic Scottsdale, Herbal Medicine and Liver Disease

10/2001

Institutional/Departmental Administrative Responsibilities, Committee Membershipsand Other Activities

Mayo Clinic

Mayo Clinic CommitteesMayo Clinic Clinical Practice Committee

Office of Information and Knowledge ManagementArizona Representative 2012 - 2015

Mayo Clinic Education CommitteeResearch & Education Academic Information Management System Oversight Committee

Member 2006 - 2015Mayo Clinic in Arizona

Arizona Research Operations Management TeamClinical Research Subcommittee

Chair 2016 - Present

Mayo Clinic Arizona CommitteesExecutive Operations Team - Arizona

Associate Medical Information Officer 2012 - 2015Clinical Practice Committee - Arizona

Member 2012 - 2015Information Technology Committee

Information Technology Advisory Prioritization Review SubcommitteeMember 2001 - 2012Vice Chair 10/2002 - 2012

Research CommitteeMember 2012 - 2015

Research Operations Management TeamVice Chair 2015 - Present

Information Technology Steering CommitteeMember 2002 - 2015

Internal Medical Research CommitteeMember 2002 - 2003

Internal Medicine Administrative CommitteeMember 2002 - 2003

Internal Medicine Executive CommitteeMember 2002 - 2003

International Activities CommitteeMember 2001 - 2003

RE-AIMS 7/22/2020 3:25:34 PM


Vaccination in Liver Transplant RecipientsConcurrent Sunrise Symposium 2005Seattle, Washington

05/2005

Vaccination Strategies for Liver Transplantation PatientsAmerican Transplantation CongressSeattle, Washington

05/2005

Living Donor Liver TransplantationAssociation of Transplanted Patients (AETHA)Zaragoza, Spain

11/2006

El Problema de la Hepatitis C Antes y Despues del Transplante HepaticoEnfermedades Hepaticas Y Transplante De Higado, Pontificia Universidad Catolica de ChileSantiago, Chile

10/2007

Evaluacion Y Manejo Actual de la Hipertension PortalEnfermedades Hepaticas Y Transplante De Higado, Pontificia Universidad Catolica de ChileSantiago, Chile

10/2007

Treatment of Hepatitis C 2009: What Are the Options?ACG 74th Annual Scientific Meeting and Postgraduate CourseSan Diego, California

10/2009

Hepatitis C: What to Do When the Treatment FailsModerator & SpeakerACG Western Regional Postgraduate CourseLas Vegas, Nevada

01/2011

SpeakerII Congreso de Medicina Interna del Oriente ColombianoBucaramanga, Colombia

06/2011

Moderator & TeacherXXIV Congreso de la Asociacion Latinoamericana para el Estudio del HigadoSantiago, Chile

09/2016 - 10/2016

Hepatitis C: Can We Afford to Treat All Patients?The AASLD Liver MeetingBoston, Massachusetts

11/2016

Predictors of Outcomes in CirrhosisSession ModeratorThe AASLD Liver MeetingBoston, Massachusetts

11/2016

Emerging Trends SymposiumProgram ChairThe AASLD Liver MeetingBoston, Massachusetts

11/2016

Hepatology Update: The Year in ReviewModeratorAmerican Association for the Study of Liver DiseasesChicago, Illinois

05/2017

OralArtificial Neuronal Network (ANN) and Genotyping of Hepatocellular Carcinoma (HCC) in Liver Transplant Recipients as Predictors of 1-Year Cancer Free SurvivalAASLD Clinic Research Single Topic Meeting.

RE-AIMS 7/22/2020 3:25:34 PM


Efficacy of Trans-Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC) in Non-Surgical CandidatesAASLD Clinic Research Single Topic Meeting.

Hepatocellular Carcinoma With and Without Hepatitis C Virus infection, A Controversial Indication for Liver Transplantation: Maybe Not!AASLD Clinic Research Single Topic Meeting.

HCV Genotypes and Outcome in HCV Infected Cirrhotic Patients Receiving Liver Transplant from HCV Positive Donors46th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1995

Influence of HCV Genotypes and HLA Matching on the Recurrence of Hepatitis in Patients Receiving Liver Transplantation for HCV - Induced End-Stage Liver DiseaseAstra Merck Young Investigators Conference in Digestive DiseasesCoeur D'alene, Idaho

04/1996

HCV Genotypes in Middle Eastern End-Stage Liver Disease Patients and Clinical Outcome of Liver Transplantation96th Annual Meeting of the American Gastroenterological AssociationSan Francisco, California

05/1996

Infective HCV Genotypes: A Final Report on HCV Genotype Influence on the Outcome of Liver Transplantation for HCV Related End-Stage Liver Disease47th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1996

A Report on HCV Genotype Influence on the Outcome of Liver Transplantation for HCV Related End-Stage Liver Disease4th Congress of the International Liver Transplantation SocietySeattle, Washington

10/1997

HCV Genotypes: A Report on HCV Genotype Influence on the Outcome of Liver Transplantation for HCV Related End-Stage Liver Disease4th Congress of the International Liver Transplantation SocietySeattle, Washington

10/1997

Intestinal Transplantation for End Stage Crohn's DiseasePresented at the 25th Annual Scientific Meeting of the American Society of Transplant SurgeonsChicago, Illinois

05/1999

Intestinal Transplantation for Patients With Visceral Vascular Occlusive Disease25th Annual Scientific Meeting of the American Society of Transplant SurgeonsChicago, Illinois

05/1999

Long Term Follow-Up of Lamivudine Therapy for Hepatitis B Before and After Liver Transplantation: Clinical Implication of Development of the YMDD Mutant50th Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

11/1999

Natural History of Barrett's Esophagus in Orthotopic Liver Transplant Recipients50th Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

11/1999

Progression of Liver Fibrosis in Patients With Chronic Hepatitis C After Orthotopic Liver Transplantation: A Final Report.50th Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

11/1999

RE-AIMS 7/22/2020 3:25:34 PM


A Case of Post-Transplantation Lymphoproliferative DisorderAmerican College of Gastroenterology 65th Annual Scientific MeetingNew York, New York

10/2000

Adefovir Dipivoxil Suppresses Lamivudine Resistant Hepatitis B Virus in Liver Transplant Recipients51st Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

10/2000

Case of Wilson's Disease and PBC Overlap51st Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

10/2000

Risk Factors and Disease Severity Among US War Veterans With Chronic Hepatitis C.50th Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

10/2000

The Natural History of Barrett's Esophagus in Orthotopic Liver Transplant RecipientsAmerican College of Gastroenterology 64th Annual Scientific MeetingNew York, New York

10/2000

Treatment of HCV Infection in an Academic Medical Center: The Experience With Interferon/Ribavirin51st Meeting of the American Association for the Study of Liver DiseasesDallas, Texas

10/2000

Changes in Hepatitis C Virus (HCV) Population in Serum and Peripheral Blood Mononuclear Cells in Chronically HCV infected Patients Receiving Liver Grafts from HCV Infected DonorsTransplant 2001 Meeting, American Society of TransplantationChicago, Illinois

05/2001

Comparison of Alpha-Interferon Alone and Alpha-Interferon and Ribavirin for the Treatment of Recurrent Hepatitis C After Liver TransplantationDigestive Diseases WeekAtlanta, Georgia

05/2001

Increased Prevalence of Osteoporosis In Patients With End-Stage Liver Disease Secondary To Hepatitis C Infection and AlcoholDigestive Diseases WeekAtlanta, Georgia

05/2001

Transmission and Evolution of Viral Quasi-Species in Hepatitis C Virus Positive Liver Transplant RecipientsTransplant 2001 Meeting, American Society of TransplantationChicago, Illinois

05/2001

The Impact of Anti-Hepatitis Bc Positive Grafts on the Outcome of Liver Transplantation for HVC-Related CirrhosisILTS LICAGE MeetingBerlin, Germany

07/2001

Transmission and Evolution of Viral Quasi-Species in Hepatitis C Virus Positive Liver Transplant RecipientILTS LICAGE MeetingBerlin, Germany

07/2001

Alpha-1 Antitrypsin Genotypes in Cirrhotic Livers With PAS-D (+) Globules: Coexistence With Other Liver Disease and Outcome After Liver Transplant (Oltx)66th Annual Scientific Meeting of the American College of GastroenterologyLas Vegas, Nevada

10/2001

RE-AIMS 7/22/2020 3:25:34 PM


Case of Wilson's Disease and PBC Overlap66th Annual Scientific Meeting of the American College of GastroenterologyLas Vegas, Nevada

10/2001

Fungal Brain Abscess Secondary To Scedosporium Apiospermum infection After Orthotopic Liver Transplantation (OLT)66th Annual Scientific Meeting of the American College of GastroenterologyLas Vegas, Nevada

10/2001

Screening Colonoscopy Prior To Orthotopic Liver Transplantation (OLT)66th Annual Scientific Meeting of the American College of GastroenterologyLas Vegas, Nevada

10/2001

Varicella-Zoster Hepatitis in An Immunocompromised Host: Resolution of Severe Hepatic Necrosis With Early Administration of Acyclovir66th Annual Scientific Meeting of the American College of GastroenterologyLas Vegas, Nevada

10/2001

Role of Mycophenolate Mofetil (MMF) on Early Recurrence of Hepatitis C Infection After Liver Transplantation2nd International Congress on ImmunosuppressionSan Diego, California

12/2001

Steatosis in Hepatitis C Genotype 3 is Associated With Intravenous Drug Abuse and Not With Fibrosis104th Annual Meeting of the American Gastroenterological AssociationOrlando, Florida

05/2003

Different Translation Efficiencies of 5'UTR Hepatitis C Virus Variants Before and After Liver Transplantation54th Annual Meeting of the American Association for the Study of Liver DiseasesBoston, Massachusetts

10/2003

Rejection Treatment Modifies Hcv Quasispecies Evolution After Liver Transplantation54th Annual Meeting of the American Association for the Study of Liver DiseasesBoston, Massachusetts

10/2003

Hepatitis C Virus Recurrence in Living Donor Liver TransplantationAmerican Transplant CongressWashington, District of Columbia

05/2004 - 06/2004

Use of Anti-HBc and Anti-HCV Donors2004 ILTS Annual CongressKyoto, Japan

06/2004

Management of Viral Hepatitis after TransplantVisiting ProfessorPucon, Chile

12/2004

Update on Liver TransplantationCourse Co-DirectorMayo Clinic Arizona - CME Course

03/2005

Non-Alcoholic SteatohepatitisMayo Clinic Jacksonville, Advances and Changing Trends in Medicine Update 2005 (CME Presentation)Miami, Florida

08/2005

Difficult Non-Hepatitis CasesBreakout Interactive SessionAmerican College of Gastroenterology Governors "Best Practices 2006" Course

01/2006

RE-AIMS 7/22/2020 3:25:34 PM


How to Keep Your Patient Alive While Awaiting for Liver TransplantationAmerican College of Gastroenterology Governors "Best Practices 2006" Course

01/2006

Portal Hypertension Management in the Liver Transplantation SettingCourse Co-DirectorMCS Winter Gastroenterology MeetingScottsdale, Arizona

02/2006 - 03/2006

How to Manage the Patient with CirrhosisClinical Reviews, Mayo Clinic ArizonaArizona

04/2006

Hepatology Problems Encountered in a Mental Health InstitutionColorado Mental Health Institute at PuebloPueblo, Colorado

05/2006

Evaluation of Late Allograft DysfunctionTransplant Hepatology Certificate of Added Qualifications (CAQ) Review Course

09/2006

Management of the Liver Transplant RecipientModeratorTransplant Hepatology Certificate of Added Qualifications (CAQ) Review Course

09/2006

Capsule Endoscopy: Is it Good Enough for Screening and Grading Esophageal varices?Course DirectorAASLD/ASGE Endoscopy CourseBoston, Massachusetts

10/2006

Endoscopy & Hepatology: Challenge and Future DirectionsCo-Director and ParticipantAASLD/ASGE Endoscopy CourseBoston, Massachusetts

10/2006

Recurrent Primary Sclerosing Cholangitis in a Patient with a Biliary LeakAASLD/ILTS Transplant CourseBoston, Massachusetts

10/2006

Take a Closer Look! Esophageal Capsule Endoscopy for Liver Disease PatientsSatellite Symposium ChairBoston Sheraton HotelBoston, Massachusetts

10/2006

What the Hepatologist Expects from a Liver Biopsy in Chronic HCVLiver Biopsy in the 21st CenturySan Sebastian, Spain

11/2006

Use of Hepatitis C Virus Donors in Liver TransplantPenn State College of MedicineHershey, Pennsylvania

04/2007

HCV Treatment: My Vision of the FutureGastroenterology and Hepatology Linked to Endoscopy: Mayo Clinic's 7th Annual Winter Course in ScottsdaleScottsdale, Arizona

02/2008

Session III - Evening SessionModeratorGastroenterology and Hepatology Linked to Endoscopy: Mayo Clinic's 7th Annual Winter Course in ScottsdaleScottsdale, Arizona

02/2008

RE-AIMS 7/22/2020 3:25:34 PM


Session VIII - General Hepatology TopicsModeratorGastroenterology and Hepatology Linked to Endoscopy: Mayo Clinic's 7th Annual Winter Course in ScottsdaleScottsdale, Arizona

02/2008

New Therapies for Hepatitis B and CMayo Clinic Presents - Advances and Changing Trends in Medicine - Update 2008Cancun, Mexico

03/2008

Hepatitis C: Difficult-to-Treat PatientsMayo Clinic Update in HepatologyChicago, Illinois

04/2008

Key Papers Published ElsewhereMayo Clinic Update in Hepatology, Best of Hepatology: 2007 in ReviewChicago, Illinois

04/2008

Treatment Strategies for HCV after TransplantationAmerican Transplant CongressToronto, Ontario, Canada

05/2008

Liver Transplantation and Downstaging for HCCLiver Disease Day (LDD)Indian Wells, California

02/2010

Hepatitis C GenotypesChallenges of Diagnosis and Treatment in Gastroenterology and HepatologySalvador Zubiran, Mexico

07/2010

Hepatitis C: Treatment and MonitoringChallenges of Diagnosis and Treatment in Gastroenterology and HepatologySalvador Zubiran, Mexico

07/2010

Management of Viral MarkersChallenges of Diagnosis and Treatment in Gastroenterology and HepatologySalvador Zubiran, Mexico

07/2010

What to do with Hepatitis C without Primary ResponseChallenges of Diagnosis and Treatment in Gastroenterology and HepatologySalvador Zubiran, Mexico

07/2010

Hepatitis C39th Annual Fall Clinics MontroseMontrose, Colorado

09/2010

Work Up of Abnormal Liver Function Tests39th Annual Fall Clinics MontroseMontrose, Colorado

09/2010

HCV Que Hacer para Facilitar Requesta Viral SostenidaVI Curso Internacional de Enfermedades Hepaticas, Associacion Colombiana de HepatologiaMedellin, Colombia

03/2011

Sindrome Metabolico y TrasplanteVI Curso Internacional de Enfermedades Hepaticas, Associacion Colombiana de HepatologiaMedellin, Colombia

03/2011

Difficult Decisions in the Treatment of Viral Hepatitis CAsociacion Mexicana de Hepatologia A.C.Veracruz, Mexico

11/2013

RE-AIMS 7/22/2020 3:25:34 PM


Challenges in Hepatitis B and CMayo Clinic Gastroenterology and Hepatology 2014Orlando, Florida

03/2014

General HepatologyModeratorMayo Clinic Gastroenterology and Hepatology 2014Orlando, Florida

03/2014

General Hepatology Q & APanel MemberMayo Clinic Gastroenterology and Hepatology 2014Orlando, Florida

03/2014

HCV Treatment for 2014: The New Direct Anti-viralsMayo Clinic Clinical Reviews 2014, 25th Annual Family Medicine and Internal Medicine UpdateScottsdale, Arizona

03/2014

Hepatitis C ManagementMayo Clinic Gastroenterology and Hepatology 2014Orlando, Florida

03/2014

How to Treat the Patient with Hepatitis C in 2014Mayo ClinicPhoenix, Arizona

05/2014

Lo Mejor of DDW en EspañolSymposium SpeakerDigestive Disease Week 2014Chicago, Illinois

05/2014

Acute Hepatitis CAsociacion Mexicana de Hepatologia A.C.Monterrey, Mexico

09/2014

Hepatitis C: Therapy without InterferonAsociacion Mexicana de Hepatologia A.C.Monterrey, Mexico

09/2014

Hepatitis: Question and Answer SessionAsociacion Mexicana de Hepatologia A.C.Monterrey, Mexico

09/2014

Presentation of Clinical CasesAsociacion Mexicana de Hepatologia A.C.Monterrey, Mexico

09/2014

High Sustained Virologic Response Rates in Liver Transplant Recipients with Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir+Dasabuvir Plus RibavirinHepatitis PlenaryAmerican Association for the Study of Liver Diseases (AASLD)Boston, Massachusetts

11/2014

Multicenter Experience using Sofosbuvir and Simeprevir with/without Ribavirin to Treat HCV Genotype 1 after Liver TransplantationTransplant Plenary IIAmerican Association for the Study of Liver Diseases (AASLD)Boston, Massachusetts

11/2014

RE-AIMS 7/22/2020 3:25:34 PM


Parallel 12: Hepatitis C: New Agents - Part 1ModeratorAmerican Association for the Study of Liver Diseases (AASLD)Boston, Massachusetts

11/2014

Preparation of the Cirrhotic Patient for Gastrointestinal EndoscopySession I: Endoscopy in Patients with Advanced Liver DiseaseAmerican Association for the Study of Liver Diseases (AASLD)Boston, Massachusetts

11/2014

The Use of Simeprevir and Sofosbuvir to Treat HCV G1 in the Liver Transplant Setting: The Experience in 3 U.S. CentersParallel 2: Antivirals, Acute Liver Failure in Liver TransplantationAmerican Association for the Study of Liver Diseases (AASLD)Boston, Massachusetts

11/2014

Current and Future Management of Prior Difficult-to-Treat HCV Patients2015 Emerging Topics in Liver Disease Conference: Innovative Trends in Liver HealthHouston

09/2015

Debate: Treat All Stages of Fibrosis of Chronic-HCV Now!2015 Emerging Topics in Liver Disease Conference: Innovative Trends in Liver HealthHouston

09/2015

Renal PatientsXI National Congress of HepatologyVera Cruz, Mexico

06/2016

Current Treatment of Hepatitis C: Individualized According to GenotypeXI National Congress of HepatologyVera Cruz, Mexico

06/2016

Management of Patients With Severe Alcoholic HepatitisACG 2016 Annual Scientific Meeting & Postgraduate CourseLas Vegas, Nevada

10/2016

The Cost of HCV TherapyACG 2016 Annual Scientific Meeting & Postgraduate CourseLas Vegas, Nevada

10/2016

Abnormal Liver Injury Tests: What to do in the Office Setting19th Annual Mayo Clinic Internal Medicine Update: Sedona 2016Sedona, Arizona

10/2016

Challenging Cases in Viral HepatitisMayo Clinic Gastroenterology and Hepatology 2017Orlando, Florida

03/2017

HCV Treatment UpdateMayo Clinic Gastroenterology and Hepatology 2017Orlando, Florida

03/2017

Non-infective Precipitating Factors and TreatmentAASLD Single Topic Conference, Acute on Chronic Liver Failure: Is it Ready for Clinical Practice? Chicago, Illinois

09/2017

Preparing The Cirrhotic Patient For EndoscopyAASLD / ASGE 2017 Annual Liver MeetingWashington, District of Columbia

10/2017

RE-AIMS 7/22/2020 3:25:34 PM


Special Issues Related to Alcoholic Hepatitis Patients in Intensive CareACLF / AASLD 2017 Annual Liver MeetingWashington, District of Columbia

10/2017

PosterDistribution of HCV Genotypes in Saudi Arabian End Stage Liver Disease Patients Undergoing Liver TransplantationIX Triennial International Symposium on Viral Hepatitis and Liver Disease MeetingRome, Italy

04/1996

Influence of HCV Genotypes and HLA Matching on the Recurrence of Hepatitis In Patients Receiving Liver Transplantation for HCV Induced End-Stage Liver DiseaseIX Triennial International Symposium on Viral Hepatitis and Liver DiseaseRome, Italy

04/1996

Core Promoter and Precore Sequences in African Patients with Hepatocellular Carcinoma96th Annual Meeting of the American Gastroenterological AssociationSan Francisco, California

05/1996

Influence of HCV Genotypes and HLA Matching on the Recurrence of Hepatitis in Patients Receiving Liver Transplantation for HCV Induced End-Stage Liver Disease96th Annual Meeting of the American Gastroenterologic AssociationSan Francisco, California

05/1996

Single-Strand Conformation Polymorphism (SSCP) Study of Hepatitis B Virus in Serum and Peripheral Blood Mononuclear CellsDigestive Disease Week and 96th Annual Meeting of the American Gastroenterological AssociationSan Francisco, California

05/1996

Comparison of Hepatitis B Virus Core Promoter Sequences in Peripheral Blood Mononuclear Cells and Serum From Patients With Hepatitis B47th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1996

Hepatitis G Virus Infection In HCV-Positive Liver Transplant Recipients47th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1996

Substitutions at Positions 1762 and 1764 Neither Change the Activity of the HBV Core Promoter Nor influence Mrna Synthesis In Vitro47th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1996

Amplification and Fusion of Long Fragments of Hepatitis C Virus Genome48th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1997

Hepatitis G Virus (HGV) infection In American Patients With Cryptogenic Cirrhosis: No Evidence for Liver Replication48th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1997

Lack of Evidence for Hepatitis G Virus Replication in Peripheral Blood Mononuclear Cells48th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1997

RE-AIMS 7/22/2020 3:25:34 PM


Natural Histological Progression of Liver Disease in Patients With Hepatitis C After Liver Transplantation48th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1997

Negative Strand is Not Detected in Peripheral Blood Mononuclear Cells and Viral Sequences are Identical to Those in Serum: A Case Against Extrahepatic ReplicationAmerican Association for the Study of Liver DiseasesChicago, Illinois

11/1997

Outcome of Liver Transplantation of HCV Positive Grafts in HCV Infected Recipients48th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1997

The Presence of Active Hepatitis C Virus Replication in Lymphoid Tissue and Various Organs in Patients Co-infected With Human Immunodeficiency Virus Type 1Joint IASL Biennial Scientific and 49th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

04/1998

Analysis of Hepatitis C Quasispecies Recovered From Peripheral Blood Mononuclear Cells and Various Tissues From Patients Infected With Human Immunodeficiency Virus Type 1: Correlation With Extrahepatic Viral ReplicationIASL Biennial Scientific and 49th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1998

Final Analysis of Ribavirin and Alpha-Interferon for the Treatment of Hepatitis C Infection After Liver Transplantation.Winner, President's Choice AwardJoint IASL Biennial Scientific and 49th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1998

Hepatitis B Virus Related Hepatocellular Carcinoma After Liver Transplantation: A Report of Three CasesJoint IASL Biennial Scientific and 49th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1998

Hepatitis C Virus Genotype and Hepatocellular Carcinoma. A Pittsburgh Experience.Joint IASL Biennial Scientific and 49th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1998

Virological Outcome of Hepatitis B and C Dual infection After Liver Transplantation: Effect of Hepatitis D Co-InfectionJoint IASL Biennial Scientific and 49th Annual Meeting of the American Association for the Study of Liver DiseasesChicago, Illinois

11/1998

Prospective Evaluation of A New Metal Stent for Treating Malignant Biliary ObstructionMeeting of the American Gastroenterological AssociationOrlando, Florida

05/1999

RE-AIMS 7/22/2020 3:25:34 PM


Screening Colonoscopy in Evaluation of Elective Orthotopic Liver Transplantation (Oltx) in Two Age PopulationsDigestive Disease Week and the 100th Annual Meeting of the American Gastroenterological AssociationOrlando, Florida

05/1999

The incidence of Colonic Adenoma In Patients Undergoing Evaluation for Liver TransplantationDigestive Disease Week and the 100th Annual Meeting of the American Gastroenterological AssociationOrlando, Florida

05/1999

Liver Biopsy in the Evaluation of Living Donors for Liver Transplantation Is UsefulAmerican Transplant CongressWashington, District of Columbia

04/2002

Sub-Clinical Myocardial Ischemia as Measured by Troponin T is Common during Liver TransplantationAmerican Transplant CongressWashington, District of Columbia

04/2002

Tacrolimus As A Liver Flush Solution Ameliorates Ischemia/Reperfusion injury Following Liver TransplantationAmerican Transplant congressWashington, District of Columbia

04/2002

Analysis of 5'UTR and E2 Region Quasispecies in Liver Transplantation103 Annual Meeting of the AGA and Digestive Diseases WeekSan Francisco, California

05/2002

Treatment of Recurrent HCV Post Orthotopic Liver Transplantation (OLT) With Pegylated interferon Alpha 2b and Ribavirin: An Update103 Annual Meeting of the AGA and Digestive Diseases WeekSan Francisco, California

05/2002

Prolonged Pre-Transplant Hospitalization Does Not increase VRE Colonization in Liver Transplant Recipients8th Annual Congress of the International Liver Transplant SocietyChicago, Illinois

06/2002

Hepatitis C Virus Recurrence in Living Donor Liver Transplantation VS. Cadaveric Liver TransplantationAmerican Journal TransplantUnited States of America

05/2003

Reversal of Hepatopulmonary Syndrome After Cadaveric and Living Donor Liver Transplantation: A Single Center ExperienceAmerican Journal Transplant May 2003United States of America

05/2003

Incidence and Effect of Downstaging Hepatocellular Carcinoma on Liver TransplantAmerican Transplant CongressWashington, District of Columbia

05/2003 - 06/2003

Outcome of Liver Transplantation (LT) for Familial Amyloidotic Polyneuropathy Type I (FAPAmerican Transplant CongressWashington, District of Columbia

05/2003 - 06/2003

RE-AIMS 7/22/2020 3:25:34 PM


Positive Economic Impact of the MELD Allocation System on Decreasing Need for Pre-Transplantation HospitalizationAmerican Transplant CongressWashington, District of Columbia

05/2003 - 06/2003

The Effect of Anti-Fungal Prophylaxis on Outcomes After Adult Living Donor Liver Transplant (LDLT)American Transplant CongressWashington, District of Columbia

05/2003 - 06/2003

Capsule Endoscopy5th International Conference on Capsule EndoscopyBoca Raton, Florida

03/2006

Changes in Tacrolimus Metabolism in Post-LT Recurrent HCV Treatment with DAA RegimensSpecial Conference on Hepatitis CAmerican Association for the Study of Liver Diseases (AASLD)/European Association for the Study of the Liver (EASL)New York, New York

09/2014

RegionalInvitedPortal Hypertension: Medical Treatments, Shunts, TIPSThomas E Starzl Transplantation Institute ConferencePittsburgh, Pennsylvania

05/1997

Portal Vein ThrombosisMedical Grand RoundsUnited States of America

08/1997

Advances in HCV TherapyMayo Infection and Immunity Research ClubRochester, Minnesota

03/2014

OralHCV in the Brain: Future DirectionsJoint ASU/Mayo Research SymposiumUnited States of America

12/2002

Update of AASLS-Viral HepatitisTucson Society of GastroenterologyTucson, Arizona

01/2006

Update of AASLS-Viral HepatitisPhoenix Society of GastroenterologyPhoenix, Arizona

01/2006

Viral HepatitisThe Best of the 2006 Annual Meetings of The American College of Gastroenterology & The American Association for the Study of Liver Disease - The Phoenix Society of GastroenterologyPhoenix, Arizona

02/2007

Review of AASLD 2007: Viral HepatitisThe Phoenix Society of GastroenterologyPhoenix, Arizona

01/2008

HBV UpdateMountain Vista Medical CenterMesa, Arizona

04/2019

RE-AIMS 7/22/2020 3:25:34 PM


Visiting ProfessorshipVisiting Professorships

The Impact of HCV on Kidney TransplantationVisiting Professor - Invited Lecture3rd Annual SW Nephrology Conference

An Update and Portal Hypertension ManagementVisiting ProfessorSecond Joint Ecuadorian and Peruvian Internal Medicine Societies ConferenceCianca, Ecuador

04/2001

The Treatment of HCV after Liver TransplantationMexican Society of TransplantationIxtapa, Mexico

09/2001

American Liver FoundationLiver Disease Update, Visiting ProfessorMayo Clinic ScottsdaleScottsdale, Arizona

10/2001

The Functional Impact of Liver DiseaseTenth National Education ConferenceAssociation of Administrative Law JudgesLas Vegas, Nevada

10/2001

Liver Cancer and TransplantationModerator for International Seminar featured by MCR, MCS, MCJNational Academy of Medicine, Mexico and Universidad Nacional Autonoma de MexicoMexico

03/2002

Hepatitis C Infected Organs and Kidney TransplantationAST Clinical Symposium Plenary SessionAmerican Transplant Congress

04/2002

Sociedad Espanola de BeneficenciaAnnual Medicine ConferencePuebla, Mexico

08/2002

Update in the Management of Hepatitis CIHC Dixie Regional Medical CenterSt. George, Utah

09/2002

Treatment of HBV in the Era of LamivudineVisiting ProfessorChilean Congress of Gastroenterology/Latin American Association for the Study of the Liver Joint ConferenceSantiago, Chile

12/2002

Viral Hepatitis and Retransplantation for Hepatitis C in an Era of Organ Shortage.Update in Liver Diseases and TransplantationAmerican Liver FoundationPhoenix, Arizona

03/2003

Update in HCV and Liver TransplantationPhoenix Indian Medical CenterPhoenix, Arizona

05/2003

RE-AIMS 7/22/2020 3:25:34 PM


State of the Art Topics in Gastroenterology and HepatologyCourse Director, Nacional de Ciencias Medicas y Nutrición-"Salvador Zubiran", Mexico DFMayo Clinic ArizonaScottsdale, Arizona

10/2003

Mexico Instituto Nacional de Ciencias Medicas y Nutrición-"Salvador Zubiran", Mexico DFVisiting Professor - Invited LectureConferencia Magistral: Transplante hepatico en E.U.A. y el mundoMexico

09/03/2004

Sociedad Chilena de TransplanteVisiting ProfessorPucon, Chile

12/2004

Update on Immunosuppression in Liver TransplantVisiting ProfessorPucon, Chile

12/2004

Update in Liver TransplantationMedical Grand Rounds Universidad Industrial de SantanderBucaramanga, Colombia

07/15/2005

Medical Grand Rounds Clinica Ardila LülleBucaramanga, Colombia

07/16/2005

ESO Pill-CamTucson Veterans Association - Grand RoundsTucson, Arizona

04/2007

Management of the Patient with Cirrhosis for the Gastroenterologist13th Carlos Rubio Memorial Visiting ProfessorshipUniversity of Puerto Rico School of Medicine, Department of Internal MedicineSan Juan, Puerto Rico

11/26/2007 - 11/28/2007

Portal Hypertension13th Carlos Rubio Memorial Visiting ProfessorshipUniversity of Puerto Rico School of Medicine, Department of Internal MedicineSan Juan, Puerto Rico

11/26/2007 - 11/28/2007

The Future of HCV13th Carlos Rubio Memorial Visiting ProfessorshipUniversity of Puerto Rico School of Medicine, Department of Internal MedicineSan Juan, Puerto Rico

11/26/2007 - 11/28/2007

Complementary Therapies in Liver Cancer While Waiting for Liver TransplantationXX Latin American and Caribbean Congress of Transplantation and the II Chilean Congress of TransplantationVina del mar, Chile

09/22/2009 - 09/26/2009

Hepatitis B and C Post-liver Transplantation - Current ManagementXX Latin American and Caribbean Congress of Transplantation and the II Chilean Congress of TransplantationVina del mar, Chile

09/22/2009 - 09/26/2009

Recurrence of Liver Disease Post-liver Transplantation and Its Management (autoimmune hepatitis, alcohol, NASH)XX Latin American and Caribbean Congress of Transplantation and the II Chilean Congress of TransplantationVina del mar, Chile

09/22/2009 - 09/26/2009

RE-AIMS 7/22/2020 3:25:34 PM


Update on HCV TreatmentMedica SurToriello Guerra, Mexico

08/2016

Research Interests and AccomplishmentsProtocols: Pegylated Interferon alfa-2b and Ribavirin after Orthotropic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy (PROTECT)- Schering-Plough A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Food Effect of R05024048 in Healthy Volunteers in Patients with Chronic HCV Infection of Genotype 1 - Pharmasset Correlation of Hepatic MRI Elastrography with Hepatic Histology in Patients Evaluated with MRI and Hepatic Biopsy - A Prospective Study - Roche A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (R0488161) When Given in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection - Roche Evaluation of Beletacept as First-line Immunosuppression in De Novo Liver Transplant Recipients - BMS A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive Procedures Completed Protocols: The Early Use of Sanvar with Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension A Randomized, Open-Label Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Hepatitis C Immune Globulin Intravenous (Human), Civacir, in Liver Transplant Recipients. A Phase IIB Clinical Trial to Evaluate the Combination of Pegylated Interferon Alf Plus Valopicitabaine (NM283) in Treatment Naive Patients with Chronic Hepatitis C A Prospective, Multicenter, Open-Label, Comparative, Efficacy Study of Pegasys Plus Copegus in Treatment-naive Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naive Non-Latino Caucasian Patients with... A Phase 2 Study of VX-950 in combination with Peginterferon alfa-2a (Pegasys®) With ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who have not Received Prior Treatment.

Research Grants Awarded

RE-AIMS 7/22/2020 3:25:34 PM


Active Grants

Federal sub award

Program Director / Principal Investigator

13-009338/Infections and Other Complications of Cirrhosis: A Prospective Multicenter Study . Funded by Grifols Therapeutics, Inc.

05/2014 - 04/2017


Mayo Clinic Center for Clinical and Translational Science (CCaTS CORE G). Funded by National Institutes of Health. (UL1 TR002377-01)

09/2017 - 06/2022


Mayo Clinic Center for Translational Science Activities (Core D). Funded by National Institutes of Health. (TR002377)

07/2018 - 06/2022


A multicenter, randomized, double blinded, placebo-controlled clinical trial of Anakinra (plus zinc), G-CSF, or prednisone in patients with severe alcoholic hepatitis by the AlcHepNet Consortium. Funded by National Institute on Alcohol Abuse and Alcoholism. (AA 26974-02)

07/2019 - 06/2023

Industry


HCV - Quasispecies Sub-Project. Funded by Roche Bioscience. (ROCHE #88S)

04/2003 - 03/2007


16-004633/ A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects with Hepatorenal Syndrome Type I. Funded by Mallinckrodt Medical, Inc.. (MNK19013058 CONFIRM site 043)

08/2016 - 08/2018


19-000798/COLLECTION OF BANKED LIVER SPECIMENS FROM PIZZ PATIENTS FOR HISTOLOGICAL ASSESSMENT. Funded by Arrowhead Pharma. (AROAAT0002)

04/2019 - 03/2020


18-005196 / Effects of Plasma Exchange with Human Serum Albumin 5% (PE-A 5%) on Short-term Survival in Subjects with "Acute-On-Chronic Liver Failure" (ACLF) at High Risk of Hospital Mortality. Funded by Grifols Therapeutics, Inc.. (IG1407)

08/2019 - 08/2020


MCA // POSEIDON; alfapump® System in the treatment of refractory or recurrent ascites: a multicenter single arm non-randomized within subject crossover design pivotal study. Funded by Sequana, Inc.. (POSEIDON)

09/2019 - 09/2022


MCA;19-006315; A Placebo-Controlled, Mullti-dose, Ph 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Pts with AATD . Funded by Arrowhead Pharma. (AROAAT2001)

11/2019 - 11/2022

Mayo Clinic

Co-Investigator MCA Site/RECOVER: Phase 2 Randomized, Double-Blind Trial TREating hospitalized patients with COVID-19 with Camostat MesilatE, a TMPRSS2 Inhibitor. Funded by Development - Gifts from benefactors

06/2020 - 05/2021

RE-AIMS 7/22/2020 3:25:34 PM


Completed Grants

Federal

Principal Investigator

HCV Quasispecies Dynamics and Liver Transplant. Funded by National Institute of Diabetes and Digestive and Kidney Diseases. (R03 DK63175)

01/2003 - 12/2005

Federal sub award


12-001669 Replacement: Contract Amendment 2/HCV-TARGET: Hepatitis C Therapeutic Registry and Research Network-A Longitudinal, Observational Study. Funded by University of Florida. (HCV Target)

09/2012 - 09/2017


SORAFENIB IN PATIENTS WITH HEPATOPULMONARY SYNDROME:. Funded by National Heart, Lung, and Blood Institute. (UM1HL116886)

07/2015 - 12/2017


TREAT - Mayo (Sub to MCR). Funded by National Institute on Alcohol Abuse and Alcoholism. (U01 AA021788)

07/2015 - 06/2018


15-000994/A (M)ulti-center, Prospective, (O)pen Label, Uncontrolled Feasibility (S)tudy to Assess the Safety & Effectiveness of an automatic low flow (A)scites (alfa) pump (I)n Patients with (C)irrhosis and Refractory or Recurrent Ascites (MOSAIC Study) . Funded by Sequana, Inc.. (2013-AAR-007)

04/2016 - 03/2018

Co-Investigator Mayo Clinic Center for Translational Science Activities . Funded by National Center for Research Resources. (UL1 TR000135-06)

09/2011 - 06/2017

Foundation


Transmission and Evolution of HCV Quasispecies After Liver Transplantation: The Importance of the 5' Untanslated Region in Long Term Outcome.. Funded by J. Orin Edson Foundation

10/2001 - 09/2002

Industry


A Randomized, Open-Label, Multicenter, Efficacy and Safety Study of Pegasys for the Treatment of Hepatitis C Virus Infection Administered to Patients Six to Sixty Months Post Liver Transplantation. Funded by Roche

03/2000 - 11/2000


A Randomized, Double Blind Comparison of Three Doses of Entecavavir vs Lamivudine in Immunocompetent Subjects with Chronic Hepatitis B Infection with Viremia on Lamivudine Therapy. Funded by Bristol Meyers Squibb

06/2000 - 11/2000


Lanreotide as an adjuvant to endoscopic ligation in pts with esophageal varices. Funded by Biomeasure, Inc.

04/2001 - 03/2002


Hoffman-LaRoche (Protocol No. NR15997) (IRB# 7-01). Funded by Hoffmann-La Roche Incorporated

04/2001 - 03/2003


NR15996: A Randomized, Open-Label, Multicenter Efficacy and Safety Study of Pegasys as a Prophylaxis Against Hepatitis C Virus Infection Recurrence after Liver Transplantation. Funded by Roche Laboratories Inc.

08/2001 - 07/2002


OT-0401: Terlipressin in Hepatorenal Syndrome. Funded by Orphan Therapeutics

04/2005 - 03/2006

RE-AIMS 7/22/2020 3:25:34 PM



1462-05/ML 18423 Calcineurin Inhibitor Free Maintenance Regimen with Mycophenolate Mofetil and Sirolimus in Recipients of an Orthotopic Liver Transplant. Funded by Roche Laboratories Inc.

09/2005 - 08/2008


RFHE3001: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaximin 550 mg BID for 6 Months in Preventing Hepatic Encephalopathy. Funded by Salix Pharmaceuticals, Inc.

05/2006 - 04/2007


ACH171-002:A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and antiviral Activity of Multiple Doses of ACH-0137171 in Subjects with Chronic Hepatitis C Infectio. Funded by Achillion Pharmaceuticals Inc

11/2006 - 10/2007


NV-02B-022: An Open Label Trial of Telvivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Studies. Funded by Idenix Pharmaceuticals, Inc.

12/2006 - 11/2009


06-007721/ MA-70: Evaluation of PillCam ESO - Simplified Ingestion Procedure (SIP) in the detection of Esophhageal Varices. Funded by Given Imaging Ltd.

03/2007 - 02/2008


06-006289/ HGS1008-C1067 ACHIEVE-2,3: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNalpha2a). Funded by Human Genome Sciences, Inc.

04/2007 - 03/2009


06-006276/HGS1008-C1060/ ACHIEVE-1: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNalpha2a) in. Funded by Human Genome Sciences, Inc.

04/2007 - 03/2010


06-006691/ Supplement-Amendment #1: ACHIEVE-1/HGS1008-C1060: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with. Funded by Human Genome Sciences, Inc.

02/2008 - 01/2009


07-007464/A PHASE II, OPEN-LABEL, MULTI-CENTER PROSPECTIVE, CONVERSION STUDY IN STABLE LIVER TRANSPLANT PATIENTS TO COMPARE THE PHARMACOKINETICS OF LCP-TACRO TABLETS ONCE-A-DAY TO PROGRAF® CAPSULES TWICE-A-DAY. Funded by Life Cycle

04/2008 - 03/2010


08-001106/A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys ®) and Ribavirin (Copegus ®) in Treatment Naïve Subjects with Genotype 1 Chronic Hepatitis C. Funded by Vertex Pharmaceuticals Incorporated

06/2008 - 05/2010


A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys ®) and Ribavirin (Copegus ®) in Treatment Naïve Subjects with Genotype 1 Chronic Hepatitis C. Funded by Vertex Pharmaceuticals Incorporated

06/2008 - 05/2010

RE-AIMS 7/22/2020 3:25:34 PM



08-002044/TPL104054 a Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing El. Funded by GlaxoSmithKline

10/2008 - 09/2010


TPL104054 a Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasiv. Funded by GlaxoSmithKline

10/2008 - 09/2010


TPL104054 a Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasiv. Funded by GlaxoSmithKline

10/2008 - 09/2010


08-005626/A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterfero. Funded by Vertex Pharmaceuticals Incorporated. (VX08-950-111)

11/2008 - 10/2010


A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a. Funded by Vertex Pharmaceuticals Incorporated. (VX08-950-111)

11/2008 - 10/2010


08-005898/A Phase 3, Safety and Efficacy Study of Boceprivir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (SPRINT). Funded by Schering-Plough

11/2008 - 10/2011


08-005898/A Phase 3, Safety and Efficacy Study of Boceprivir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (SPRINT). Funded by Schering-Plough

11/2008 - 10/2011


08-007672/LifeCycle 2018/A PHASE 2, OPEN-LABEL, MULTI-CENTER, RANDOMIZED TRIAL TO. Funded by Life Cycle. (2018)

01/2009 - 12/2010


LifeCycle 2018/A PHASE 2, OPEN-LABEL, MULTI-CENTER, RANDOMIZED TRIAL TO. Funded by Life Cycle. (2018)

01/2009 - 12/2010


08-007899/Idenix IDX-08C-003: A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1. Funded by Idenix Pharmaceuticals, Inc.. (IDX-08C-003)

03/2009 - 02/2010


M10-380/A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination with Pegylated Interferon (pegIFN) and Ribavirin (RBV) in S. Funded by Abbott Laboratories. (M10-380)

05/2009 - 04/2010

RE-AIMS 7/22/2020 3:25:34 PM



A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AST-120 (SPHERICAL CARBON ADSORBENT) FOR 8 WEEKS IN THE TREATMENT OF MILD HEPATIC ENCEPHALOPATH. Funded by Ocera Therapeutics Inc . (AST-MHE201)

06/2009 - 05/2010


A PHASE 2, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING TRIAL TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF AST-120 (SPHERICAL CARBON ADSORBENT) FOR 8 WEEKS IN THE TREATMENT OF MILD HEPATIC ENCEPHALOPATH. Funded by Ocera Therapeutics Inc . (AST-MHE201)

06/2009 - 05/2010


09-000627/Schering-Plough P05514/A Single-Arm Study to Provide Boceprivir Treatment in Subjects with Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies (Provide). Funded by Schering-Plough. (P05514)

06/2009 - 05/2011


A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1,2,or 3 ABT-333 Clinical Studies. Funded by Abbott Laboratories. (M10-459)

06/2009 - 05/2011


A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in Combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys an. Funded by Hoffmann-La Roche Incorporated. (NV21075)

08/2009 - 07/2011



08/2009 - 07/2011



08/2009 - 07/2011


A Phase 2, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety, and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used Up to 7 Days in Subjects with Chronic Liver Diseas. Funded by Eisai . (E5501-G000-202)

08/2009 - 08/2011



08/2009 - 08/2011



08/2009 - 08/2011

RE-AIMS 7/22/2020 3:25:34 PM



An open-label, multicenter protocol providing pegylated interferon alfa-2a (PEGASYS®) as monotherapy or in combination with ribavirin (COPEGUS®) for patients with chronic hepatitis C who have participated in previous Roche or Roche partner protocols. Funded by Hoffmann-La Roche Incorporated. (NV21928B)

10/2009 - 10/2011


A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS-9450 in Adults with Chronic Hepatitis C Virus Infection (GS-US-227-0106). Funded by Gilead Sciences. (GS-US-227-0106)

10/2009 - 10/2011


A Phase 2b, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GS-9450 in Adults with Chronic Hepatitis C Virus Infection (GS-US-227-0106). Funded by Gilead Sciences. (GS-US-227-0106)

10/2009 - 10/2011


09-006473/ IDX-08C-004/ A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin in Subjects with Genotype 1 Chronic Hepatitis C Infection. Funded by Idenix Pharmaceuticals, Inc.. (IDX-08C-004)

01/2010 - 01/2012


P06086/Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia . Funded by Schering Plough. (P06086)

01/2010 - 01/2012


A randomized, adaptive design dose finding study to assess the antiviral efficacy and safety of NIM811 administered in combination with Standard of Care (SOC) for 12 weeks in relapsed HCV-1 infected patients. Funded by Novartis. (CNIM811B2202)

02/2010 - 02/2012


A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 with Ritonavir (ABT-450/r) ABT-333 or ABT-072 Each Administered Alone and. Funded by Abbott Laboratories. (M11-602)

04/2010 - 04/2012


A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 with Ritonavir (ABT-450/r) ABT-333 or ABT-072 Each Administered Alone and. Funded by Abbott Laboratories. (M11-602)

04/2010 - 04/2012


526H04/ Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naïve Subjects with Chronic Hepatitis C Virus Infection. Funded by ZymoGenetics, Inc.. (526H04)

05/2010 - 05/2012


526H04/ Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination with Ribavirin to Treatment-Naïve Subjects with Chronic Hepatitis C Virus Infection. Funded by ZymoGenetics, Inc.. (526H04)

05/2010 - 05/2012


10-001744/COLO400A2430/A Multi-Center, Randomized, Open Label, Controlled Study to Compare the Sustained Virological Response During Treatment with Neoral or Tacrolimus in Maintenance Liver Transplant Recipients Treated with Pegylated Interfer. Funded by Novartis. (COLO400A2430)

08/2010 - 08/2012

RE-AIMS 7/22/2020 3:25:34 PM



10-006765/ IK-4001-HRS-301/ MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO CONFIRM THE REVERSAL OF HEPATORENAL SYNDROME TYPE I WITH LUCASSIN® (TERLIPRESSIN) (REVERSE TRIAL). Funded by Ikaria Therapeutics. (AIk-4001-HRS-301)

03/2011 - 03/2012


11-008022/ VX11-950-114/ A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype. Funded by Vertex Pharmaceuticals Incorporated. (VX11-950-114)

04/2011 - 03/2013


TMC435-TiDP16/A Phase III Randomized, Double blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of TMC- 435 vs placebo as part of a treatment regimen including Pegylated Interferon alpha 2a and Ribavirin in Treatme. Funded by Tibotec Pharmaceuticals. (TMC435-TiDP16)

04/2011 - 04/2013


The D-LITE Study: Direct Antiviral Agents plus Lambda Interferon Treatment Evaluation.. Funded by Bristol-Myers Squibb Pharmaceutical. (AI452008)

06/2011 - 05/2014


1220.47/ A phase III, randomised, double-blind and placebo-controlled study of once daily BI 201335 120 mg for 24 weeks and BI201335 240 mg for 12 weeks in combination with pegylated interferon-a and ribavirin in treatment-naive patients with g. Funded by Boehringer Ingelheim. (1220.47)

08/2011 - 08/2014


11-002520/IDX-08C-005/ A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination with Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Infection. Funded by Idenix Pharmaceuticals, Inc.. (IDX-08C-005)

09/2011 - 09/2013


11-002518/ MK5172-003/A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly with Peginterferon alfa-2b and Ribavirin in T. Funded by Merck & Co., Inc.. (MK5172-003)

11/2011 - 11/2013


11-008007 Replacement budget - Amendment 1/ M11-652/ A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 With and Wi. Funded by AbbVie Inc.. (M11-652)

01/2012 - 01/2014


11-008007/ M11-652/ A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, . Funded by Abbott Laboratories. (M11-652)

01/2012 - 01/2014


11-007276 A Multi-Center Double-blind Randomized Controlled Study to Determine the Safety and Pharmacokinetics of ifetroban in Hepatorenal Syndrome. Funded by Cumberland Pharmaceuticals, Inc.. (CPIIFE001)

05/2012 - 05/2014

RE-AIMS 7/22/2020 3:25:34 PM



12-002516 AI4444-052-114 A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared with Telaprevir in Combination with PEg-Inteferon Alfa-2a and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis-C. Funded by Bristol Meyers Squibb. (BMS AI444-052-114)

06/2012 - 06/2014


12-000916/VX11-950-117/ A 2-Part, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected with Genotype 1 Hepatitis C Virus Following Liver Transplantation. Funded by Vertex Pharmaceuticals Incorporated. (VX11-950-117)

06/2012 - 06/2014


12-004403 replacement budget-Amendment 1/GX-US-174-0172 Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy. Funded by Gilead Sciences. (GX-US-174-0172)

10/2012 - 10/2017


12-004403/GX-US-174-0172 Prospective, Observational, Post-marketing Renal Safety Surveillance Registry in Patients with Chronic Hepatitis B (HBV) Infection with Decompensated Liver Disease Receiving Nucleotide/side Therapy While on the Orthotopic Liver Tr. Funded by Gilead Sciences. (GX-US-174-0172)

10/2012 - 10/2017


12-007959/AI452017 A Phase 3, Randomized, Double-Blind, Controlled Study Efficacy/Safety of Peginterferon Lambda-1a, w/w/o Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combo w RIB, in the Treatment of Naïve Genotype 2&3 Chronic HepC . Funded by Bristol Meyers Squibb. (AI452017)

01/2013 - 01/2015


12-008193/M13-099: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267(ABT-450/r/ABT-267) and ABT-333 Coadministered with Ribavirin (RBV) in Adults with Genotype 1 Chronic HCV Infection and Cirrho (TURQUOISE-II). Funded by AbbVie Inc.. (M13-99)

01/2013 - 01/2015


12-009840/GS-US-337-0109: A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy+Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12+24 Wks in Treatment-Experienced Subjects w Chronic Genotype 1 HCV Infection. Funded by Gilead Sciences. (GS-US-337-0109)

02/2013 - 01/2015


13-000412 Replacement/CTA Amend1/M12-999/ Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combo of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered w RBV in Adult Liver Transplant Recipients w G. Funded by AbbVie Inc.

03/2013 - 03/2015


13-000412/M12-999/ Open-label, Single Arm, Phase 2 Study to Evaluate the Safety and Efficacy of the Combo of ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered w RBV in Adult Liver Transplant Recipients w Genotype 1 HCV Infection. Funded by AbbVie Inc.

03/2013 - 03/2015


13-002784/GS-US-248-0122/A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection . Funded by Gilead Sciences. (GS-US-248-0122)

08/2013 - 07/2016

RE-AIMS 7/22/2020 3:25:34 PM



13-002785/GS-US-248-0123/A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection. Funded by Gilead Sciences

08/2013 - 07/2016


13-004596/M13-102/A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) In. Funded by AbbVie Inc.. (M13-102)

10/2013 - 09/2016


13-004713/GS-US-337-0123/A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combo + Ribavirin Administered in Subjects Infected w/ Chronic HCV who have Adv Liver Disease or are Post-Liver Tx. Funded by Gilead Sciences. (GS-US-337-0123)

11/2013 - 10/2015


13-008902/E5501-311/A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults with Thrombocytopenia Associated with Liver Disease Prior to a. Funded by Eisai Company LTD. (E5501-311)

03/2014 - 02/2016


13-009087/M13-595/A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV) Infect. Funded by AbbVie Inc.. (M13-595)

04/2014 - 03/2016


14-000576/MK5172-052/A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney Disease . Funded by Merck & Co., Inc.. (MK5172-052)

05/2014 - 04/2016


14-002599 CTA Amendment 1/MK5172-068/A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the CombinationRegimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with PegylatedInterferon and Ribavirin (P/R) . Funded by Merck & Co., Inc.

07/2014 - 06/2016


14-002599/MK5172-068/A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the CombinationRegimen of MK-5172/MK-8742 in Subjects who have Failed Prior Treatment with PegylatedInterferon and Ribavirin (P/R) . Funded by Merck & Co., Inc.

07/2014 - 06/2016


14-005272/A Multicenter Treatment Protocol of Declatasvir (BMS-790052) in Combination with Sofosbuvir for the Treatment of Post-Liver Transplant Subjects with Chronic Hepatitis C (Protocol AI444257). Funded by Bristol-Myers Squibb Research and Development. (AI444257)

09/2014 - 08/2015


14-004338/GS-US-342-1137/A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis . Funded by Gilead Sciences. (GS-US-342-1137)

09/2014 - 08/2016


A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis (GS-US-342-1137). Funded by Gilead Sciences. (Protocol GS-US-342-1137)

09/2014 - 08/2016

RE-AIMS 7/22/2020 3:25:34 PM



14-005647/M14-490/An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults with Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III). Funded by AbbVie Inc.. (M14-490)

10/2014 - 09/2015


14-007270/CTA AMEND 1 and 2 / M14-868/A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety & Pharmacokinetics of Co-Administration of ABT-493 & ABT-530 With & Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or . Funded by AbbVie Inc.. (M14-868)

01/2015 - 12/2015


14-007270/CTA Amend 3/ M14-868/A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety & Pharmacokinetics of Co-Administration of ABT-493 & ABT-530 With & Without RBV in Subj With Chronic Hepatitis C Virus (HCV) Genotype 2 . Funded by AbbVie Inc.. (M14-868)

01/2015 - 12/2015


14-007270/M14-868/A Randomized Open-Label Multicenter Study to Evaluate the Efficacy Safety & Pharmacokinetics of Co-Administration of ABT-493 & ABT-530 With & Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 or Genotype 3 Infection. Funded by AbbVie Inc.. (M14-868)

01/2015 - 12/2015


ACT:15-001053/M14-226/RUBY-1/Open-Label Study to Eval Safety & Efficacy of Ombitasvir/ABT-450/Ritonavir & Dasabuvir w/wo RBV in Treatment-Naive Adults w/ Gen 1 Chr HCV, w/Severe Renal Impair or ESRD. Funded by AbbVie Inc.. (M14-226)

04/2015 - 03/2017


15-009167/ACTFP-A Randomized, OL, AC, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT 530 to Sofosbuvir Co-Administered w Daclatasvir in Adults with Chronic Hep. Funded by AbbVie Inc.. (M13-594)

02/2016 - 02/2017


Original & CTA Amend 1 / 17-003462/Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis. Funded by Conatus Pharmaceuticals. (IDN-6556-17)

08/2017 - 08/2020


17-004588/Protocol M16-135/GLE PIB in Treatment Naïve Adults with Chronic HCV Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis. Funded by AbbVie Inc.

10/2017 - 10/2018


17-008128/ CTA Amd 2/ A RETROSPECTIVE MEDICAL RECORD REVIEW STUDY TO CHARACTERIZE ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)-ASSOCIATED LIVER DISEASE. Funded by Arrowhead Pharma. (AROAAT0001)

12/2017 - 12/2018


IRB#18-002337/Prevention of Mortality with Long-Term Administration of Human Albumin in Subjects with Decompensated Cirrhosis and Ascites . Funded by Grifols Therapeutics, Inc.. (IG1601)

06/2018 - 06/2019

Co-Investigator A Multi-Center Group to Study Acute Liver Failure. Funded by NIH 10/1997 - 11/2000

Co-Investigator Intron A (Interferon alpha-2b)Plus Ribavirin Versus Placebo for Treatment of Patients with Chronic Hepatitis C and Who Are At Least Six Months Post Liver Transplantation. Funded by Schering Plough

03/1998 - 11/2000

Co-Investigator Multicenter Randomized Trial of DSRS versus TIPS. NIH Sponsored Portal Hypertension Trial. Funded by NIH

04/1998 - 11/2000

RE-AIMS 7/22/2020 3:25:34 PM


Co-Investigator An Open Label Pilot Study Investigating the Efficacy and Safety of the Perioperative Administration of PROCRITTM (Epoetin Alfa) in Blood Conservation for Status 2B Adult Patients Undergoing Liver Transplantation. Funded by Ortho Biotech

10/1998 - 11/2000

Co-Investigator Maribavir Versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants. Funded by ViroPharma Incorporated

08/2007 - 07/2009

Co-Program Director / Principal Investigator

07-006219/A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given In Combination with Pegasys and Copegus Versus the Currently Approved Combi. Funded by Hoffmann-La Roche Incorporated

01/2008 - 12/2010

Co-Investigator 07-008455/ A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination with Corticosteroids, for the Treatment of Autoimmune Hepatitis. Funded by Life Cycle

05/2008 - 10/2009

Co-Program Director / Principal Investigator

Extension: Evaluation of Belatacept as First-line Immunosuppression in De Novo Liver Transplant Recipients. Funded by Bristol-Myers Squibb Pharmaceutical

05/2009 - 04/2011

Co-Investigator CA182034: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib + Best Supportive Care (BSC) vs placebo + BSC in Subjs with Advanced Hepatocellular Carcinoma (HCC):The BRISK PS Study . Funded by Bristol-Myers Squibb Pharmaceutical. (CA182034)

12/2010 - 12/2013

Co-Investigator CA182-033: A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma . Funded by Bristol-Myers Squibb Pharmaceutical. (CA182033)

01/2011 - 01/2014

Co-Investigator A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects with Chronic HCV Infection and Child-Pugh Class B Cirrhosis (GS-US-342-1137). Funded by Gilead Sciences. (Protocol GS-US-342-1137)

09/2014 - 08/2016

Mayo Clinic


Hepatitis C Virus Infection Of The Central Nervous System: Investigation Of The Clinical Consequences And Response To Anti-Viral Therapy. Funded by CR20 Mayo Clinic Scottsdale

01/2003 - 12/2004


Hepatitis C - anti-viral therapy. Funded by Mayo Protocol 09/2003 - 08/2005


11-004771/ Hepatitis C Biobank. Funded by Core budget of PI 10/2011 - 10/2013


13-000611/Validation of HCV Aggressiveness Score (HAS) in MCA Liver Transplant Population. Funded by Discretionary Funds

02/2013 - 02/2015


14-005704/sweep/ The Utility of Vibration Controlled Transient Elastography (VCTE) for Identification of Hepatic Fibrosis in Patients Evaluated for Cardiac Transplantation or Left Ventricular Assist Device: A Pilot Study. Funded by To Be Named

10/2014 - 09/2015

RE-AIMS 7/22/2020 3:25:35 PM



17-010793 Dr. Vargas Cognitive Tests in Cirrhotic Patients. Funded by PI Sweep Account

03/2018 - 03/2019

Co-Investigator PROSPECTIVE ANALYSIS OF PREDICTORS OF NEW ONSET DIABETES AFTER LIVER TRANSPLANTATION. Funded by CR Protocol Program (Incl CR5 and CR10)

01/2010 - 01/2012

Co-Investigator CR20/ PREDICTIVE VALUE OF INFLAMMATION AND FIBROSIS IN SKELETAL MUSCLE FOR LIVER HISTOPATHOLOGY IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE; IMPACT OF MUSCLE INSULIN RESISTANCE ON THE PATHOGENESIS OF NON ALCOHOLIC STEATOHEPATITIS (NASH). Funded by CR20 - Clinical Research, 20% PI Effort

11/2010 - 11/2012

Co-Investigator Identification of a Sensitive and Accurate Diagnostic Indicator of Fibrotic Stage in Patients with Chronic Liver Disease. Funded by TGen Mayo Seed Grant

08/2011 - 07/2012

RE-AIMS 7/22/2020 3:25:35 PM


Peer-reviewed Articles

1. Hubbell HR, Vargas HE, Tsujimoto KL, Gibson GD, Pequignot EC, Bigler RD, Carter WA, Strayer DR. Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft. Cancer Immunol Immunother. 1992; 35(3):151-7. PMID: 1638550

2. DiSario JA, Burt RW, Vargas H, McWhorter WP. Small bowel cancer: epidemiological and clinical characteristics from a population-based registry. Am J Gastroenterol. 1994 May; 89(5):699-701. PMID: 8172140

3. Laskus T, Wang LF, Rakela J, Vargas H, Pinna AD, Tsamandas AC, Demetris AJ, Fung J. Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors. Virology. 1996 Jun 1; 220(1):171-6. PMID: 8659109

4. Vargas HE, Wang LF, Laskus T, Poutous A, Lee R, Demetris A, Dodson F, Casavilla A, Fung J, Gayowski T, Singh N, Marino I, Rakela J. Distribution of infecting hepatitis C virus genotypes in end-stage liver disease patients at a large American transplantation center. J Infect Dis. 1997 Feb; 175(2):448-50. PMID: 9203670

5. Laskus T, Wang LF, Radkowski M, Vargas H, Cianciara J, Poutous A, Rakela J. Comparison of hepatitis B virus core promoter sequences in peripheral blood mononuclear cells and serum from patients with hepatitis B. J Gen Virol. 1997 Mar; 78(Pt 3):649-53. PMID: 9049417

6. Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C, Morelli F, Laskus T, Fung JJ, Rakela J, Starzl TE. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation. 1997 Aug 15; 64(3):422-6. PMID: 9275107 PMCID: 2957291

7. Vargas HE, Laskus T, Radkowski M, Poutous A, Wang LF, Lee R, Dodson F, Gayowski T, Singh N, Marino IR, Fung JJ, Zhang-Keck ZY, Kim JP, Rakela J. Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation. 1997 Sep 15; 64(5):786-8. PMID: 9311724

8. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses. J Virol. 1997 Oct; 71(10):7804-6. PMID: 9311866 PMCID: 192133

9. Wang LF, Radkowski M, Vargas H, Rakela J, Laskus T. Amplification and fusion of long fragments of hepatitis C virus genome. J Virol Methods. 1997 Nov; 68(2):217-23. PMID: 9389412

10. Laskus T, Wang LF, Radkowski M, Jang SJ, Vargas H, Dodson F, Fung J, Rakela J. Hepatitis G virus infection in American patients with cryptogenic cirrhosis: no evidence for liver replication. J Infect Dis. 1997 Dec; 176(6):1491-5. PMID: 9395359

11. Vargas HE, Laskus T, Wang LF, Radkowski M, Poutous A, Lee R, Demetris JA, Gayowski T, Marino IR, Singh N, Dodson F, Casavilla A, Fung JJ, Rakela J. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg. 1998 Jan; 4(1):22-7. PMID: 9457963

12. Radkowski M, Wang LF, Vargas H, Rakela J, Laskus T. Lack of evidence for GB virus C/hepatitis G virus replication in peripheral blood mononuclear cells. J Hepatol. 1998 Feb; 28(2):179-83. PMID: 9514528

13. Laskus T, Radkowski M, Nowicki M, Wang LF, Vargas H, Rakela J. Association between hepatitis B virus core promoter rearrangements and hepatocellular carcinoma. Biochem Biophys Res Commun. 1998 Mar 27; 244(3):812-4. PMID: 9535748

14. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Detection of hepatitis G virus replication sites by using highly strand-specific Tth-based reverse transcriptase PCR. J Virol. 1998 Apr; 72(4):3072-5. PMID: 9525631 PMCID: 109756

15. Laskus T, Radkowski M, Wang LF, Jang SJ, Vargas H, Rakela J. Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic viral replication. Virology. 1998 Aug 15; 248(1):164-71. PMID: 9705266

Bibliography

RE-AIMS 7/22/2020 3:25:35 PM


16. Radkowski M, Wang LF, Vargas HE, Rakela J, Laskus T. Detection of hepatitis C virus replication in peripheral blood mononuclear cells after orthotopic liver transplantation. Transplantation. 1998 Sep 15; 66(5):664-6. PMID: 9753352

17. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. The presence of active hepatitis C virus replication in lymphoid tissue in patients coinfected with human immunodeficiency virus type 1. J Infect Dis. 1998 Oct; 178(4):1189-92. PMID: 9806058

18. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative- strand viral RNA in various tissues. Hepatology. 1998 Nov; 28(5):1398-401. PMID: 9794927

19. Chopra K, Vargas H, Demetris A, Blakolmer K, Dvorchick I, Laskus T, Wang LF, Araya V, Dodson F, Fung J, Rakela J. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation: a final report. Hepatology. 1999; 30(4):331.

20. Vargas HE, Gerber D, Abu-Elmagd K. Management of portal hypertension-related bleeding. Surg Clin North Am. 1999 Feb; 79(1):1-22. PMID: 10073179

21. Radkowski M, Wang LF, Vargas H, Rakela J, Laskus T. Hepatitis C virus in peripheral blood mononuclear cells from a chronically infected patient receiving liver graft from infected donor. Transplantation. 1999 Feb 27; 67(4):627-9. PMID: 10071038

22. Vargas HE, Rakela J. Liver transplantation for variceal hemorrhage. Gastrointest Endosc Clin N Am. 1999 Apr; 9(2):347-53. PMID: 10333447

23. Vargas HE, Laskus T, Wang LF, Lee R, Radkowski M, Dodson F, Fung JJ, Rakela J. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology. 1999 Jul; 117(1):149-53. PMID: 10381921

24. Taniguchi M, Shakil AO, Vargas HE, Laskus T, Demetris AJ, Gayowski T, Dodson SF, Fung JJ, Rakela J. Clinical and virological response of hepatitis B and C viral co-infection after liver transplantation: effect of viral hepatitis D. Liver Transpl Surg. 2000; 6(1):92-6.

25. Vargas HE, Whitcomb DC. Hepatitis C For Half A Century. Gastroenterology. 2000; 119:1405-1407. PMID: 11054403

26. De Vera ME, Reyes J, Mazariegos G, Schaefer N, Vargas H, Bond G, Wu T, Fung J, Starzl TE, Abu-Elmagd K. Isolated intestinal versus composite visceral allografts: causes of graft failure. Transplant Proc. 2000; 32:1221-2. PMID: 10995919 PMCID: 2957096

27. Gayowski, T, Singh, N, Keyes L, Wannstedt CF, Wagener MM, Vargas HE, Laskus T, Rakela J, Fung JJ, Marino IR. Late-onset renal failure after liver transplantation: role of posttransplant alcohol use. Transplantation. 2000; 69(3):383-8. PMID: 10706047

28. Paterson DL, Gayowski T, Wannstedt CF, Wagener MM, Marino IR, Vargas H, Laskus T, Rakela J, Singh, N. Quality of life in long-term survivors after liver transplantation: impact of recurrent viral hepatitis C virus hepatitis. Clin Transplant. 2000; 14(1):48-54. PMID: 10693635

29. Laskus T, Wang LF, Radkowski M, Vargas H, Nowicki M, Wilkinson J, Rakela J. Exposure of hepatitis C virus (HCV) RNA-positive recipients to HCV RNA-positive blood donors results in rapid predominance of a single donor strain and exclusion and/or suppression of the recipient strain. J Virol. 2001 Mar; 75 (5):2059-66 PMID: 11160710 PMCID: 114790 DOI: 10.1128/JVI.75.5.2059-2066.2001

30. Vargas HE. The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host. Liver Transpl. 2001 Mar; 7(3):279-81. PMID: 11244173 DOI: 10.1002/lt.500070319

31. Kashyap R, Jain A, Nalesnik M, Carr B, Barnes J, Vargas HE, Rakela J, Fung J. Clinical significance of elevated alpha-fetoprotein in adults and children. Dig Dis Sci. 2001 Aug; 46(8):1709-13. PMID: 11508671

32. Radkowski M, Wang LF, Vargas H, Wilkinson J, Vargas H, Rakela J, Laskus T. Changes in hepatitis C virus population in serum and peripheral blood mononuclear cells in chronically infected patients receiving liver graft from infected donors. Transplantation. 2001 Sep 15; 72 (5):833-8 PMID: 11571446 DOI: 10.1097/00007890-200109150-00016

RE-AIMS 7/22/2020 3:25:35 PM


33. Vargas HE, Dodson FS, Rakela J. A concise update on the status of liver transplantation for hepatitis B virus: the challenges in 2002. Liver Transpl. 2002 Jan; 8: (1)2-9. PMID: 11799479 DOI: 10.1053/jlts.2002.29765

34. Ahmad J, Vargas H, Balan V, Rakela J, Shakil AO. A randomized, double-blind, placebo-controlled trial of interferon-alpha and amantidine versus interferon-alpha alone in the treatment of patients with chronic hepatitis C. Dig Dis Sci. 2002; 47(7):1655-6. PMID: 12141832

35. Arenas JI Fasola CG Rakela J Wilkinson JK, Laskus T, Vargas H, Klintmalm G. Analysis Of 5'UTR And E2 Region Quasispecies In Liver Transplantation. Gastroenterology. 2002; 123:80.

36. Radkowski M, Wilkinson J, Nowicki M, Adair D, Vargas H, Ingui C, Rakela J, Laskus T. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol. 2002 Jan; 76 (2):600-8 PMID: 11752151 PMCID: 136845 DOI: 10.1128/jvi.76.2.600-608.2002

37. Laskus T, Radkowski M, Wilkinson J, Vargas H, Rakela J. The origin of hepatitis C virus reinfecting transplanted livers: Serum-derived versus peripheral blood mononuclear cell-derived virus. J Infect Dis. 2002 Feb 15; 185(4):417-21. PMID: 11865392

38. Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE. Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. Transplantation. 2002 May 27; 73(10):1598-602. PMID: 12042646

39. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, Nowicki M, Nikolopoulou GB, Vargas H, Rakela J. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. J Virol. 2002 Oct; 76 (19):10064-8 PMID: 12208987 PMCID: 136534 DOI: 10.1128/jvi.76.19.10064-10068.2002

40. Rakela J, Vargas HE. Hepatitis C: Magnitude of the problem. Liver Transpl. 2002 Oct; 8(10 Suppl 1):S3-6. PMID: 12362291

41. Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD, Harrison ME, Mulligan DC, Olden K, Adair D, Rakela J. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transpl. 2002 Nov; 8(11):1014-9. PMID: 12424714

42. Rodriguez-Luna H, Arenas J, Vargas HE. The use of virologically compromised organs in liver transplantation. Clin Liver Dis. 2003 Aug; 7 (3):573-84, vi PMID: 14509527 DOI: 10.1016/s1089-3261(03)00056-4

43. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl. 2003 Nov; 9(11):1129-44. PMID: 14586872

44. Arenas JI, Vargas HE, Rakela J. The use of hepatitis C-infected grafts in liver transplantation. Liver Transpl. 2003 Nov; 9(11 Suppl 3):S48-S51. PMID: 14586895

45. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, Araya VR, Dodson F, Fung JJ, Rakela J, Vargas HE. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation. 2003 Nov 27; 76(10):1487-91. PMID: 14657691

46. Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. Clin Gastroenterol Hepatol. 2004; 2:183-197. PMID: 15017601

47. Sharma P, Balan V, Hernandez J, Rosati M, Williams J, Rodriguez-Luna H, Schwartz J, Harrison E, Anderson M, Byrne T, Vargas HE, Douglas DD, Rakela J. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci. 2004 Jan; 49 (1):25-9 PMID: 14992430 DOI: 10.1023/b:ddas.0000011597.92851.56

48. Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci. 2004 Jan; 49 (1):38-41 PMID: 14992432 DOI: 10.1023/b:ddas.0000011599.78222.9e

49. Sharma P, Balan V, Hernandez JL, Harper AM, Edwards EB, Rodriguez-Luna H, Byrne T, Vargas HE, Mulligan D, Rakela J, Wiesner RH. Liver transplantation for hepatocellular carcinoma: The MELD impact. Liver Transpl. 2004 Jan; 10(1):36-41. PMID: 14755775

50. Gallegos-Orozco JF, Vargas HE. Recurrent hepatitis C virus after liver transplantation: The role of quasispecies complexity and diversity. Curr Opin Organ Transplant. 2004; 9(2):103. PMID: 0

RE-AIMS 7/22/2020 3:25:35 PM


51. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation. 2004 Jan 27; 77 (2):190-4 PMID: 14742979 DOI: 10.1097/01.TP.0000100481.14514.BB

52. Rodriguez-Luna H, Vargas HE. Natural history of hepatitis C and outcomes following liver transplantation. Minerva Gastroenterol Dietol. 2004 Mar; 50(1):51-9. PMID: 15719006

53. Carey EJ, Douglas DD, Balan V, Vargas HE, Byrne TJ, Moss AA, Mulligan DC. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: a single-center experience. Liver Transpl. 2004 Apr; 10: (4)529-33. PMID: 15048796 DOI: 10.1002/lt.20127

54. Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C virus quasi-species dynamics predict progression of fibrosis after liver transplantation. J Infect Dis. 2004 Jun 1; 189(11):2037-46. PMID: 15143471

55. Rodriguez-Luna H, Vargas HE, Williams J, De Petris G, Rakela J, Douglas DD. Primary biliary cirrhosis and systemic amyloidosis, a new association. Dig Dis Sci. 2004 Aug; 49 (7-8):1196-200 PMID: 15387346 DOI: 10.1023/b:ddas.0000037812.86212.99

56. Rodriguez-Luna H, Balan V, Sharma P, Byrne T, Mulligan D, Rakela J, Vargas HE. Hepatitis C virus infection with hepatocellular carcinoma: not a controversial indication for liver transplantation. Transplantation. 2004 Aug 27; 78 (4):580-3 PMID: 15446318 DOI: 10.1097/01.tp.0000129797.30999.69

57. Laskus T, Wilkinson J, Gallegos-Orozco JF, Radkowski M, Adair DM, Nowicki M, Operskalski E, Buskell Z, Seeff LB, Vargas H, Rakela J. Analysis of hepatitis C virus quasispecies transmission and evolution in patients infected through blood transfusion. Gastroenterology. 2004 Sep; 127 (3):764-76 PMID: 15362033 DOI: 10.1053/j.gastro.2004.06.005

58. Arenas JI, Vargas HE. Hepatitis C virus antiviral therapy in patients with cirrhosis. Gastroenterol Clin North Am. 2004 Sep; 33 (3):549-62, ix PMID: 15324943 DOI: 10.1016/j.gtc.2004.04.006

59. Gallegos-Orozco JF, Vargas HE, Rakela J. Virologically compromised donor grafts in liver transplantation. J Hepatol. 2004 Oct; 41(4):512-21. PMID: 15464230

60. Rodriguez-Luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl. 2005 May; 11(5):479-89. PMID: 15838917

61. Rodriguez-Luna H, Vargas HE, Byrne T, Rakela J. Artificial neural network and tissue genotyping of hepatocellular carcinoma in liver-transplant recipients: prediction of recurrence. Transplantation. 2005 Jun 27; 79 (12):1737-40 PMID: 15973178 DOI: 10.1097/01.tp.0000161794.32007.d1

62. Orrego M, Guo LS, Reeder C, De Petris G, Balan V, Douglas DD, Byrne T, Harrison E, Mulligan D, Rodriguez-Luna H, Moss A, Reddy K, Rakela J, Vargas HE. Hepatic B-cell non-Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transpl. 2005 Jul; 11(7):796-9. PMID: 15973702

63. Rodriguez-Luna H, Vargas HE, Moss A, Reddy KS, Freeman RB, Mulligan D. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant. 2005 Sep; 5(9):2244-7. PMID: 16095504

64. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transpl. 2006 Apr; 12(4):560-5. PMID: 16555313 DOI: 10.1002/lt.20660

65. Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver transplantation in the MELD era: a single-center experience. Dig Dis Sci. 2006 Jun; 51 (6):1070-8 PMID: 16865573 DOI: 10.1007/s10620-006-8011-1

66. Orrego M, Vargas HE, Balan V, Wells C, Harrison ME, Larson J, Huettl E, Liu PT. Portal hypertension due to a splenic arteriovenous fistula: a case report. Dig Dis Sci. 2006 Jun; 51 (6):1113-6 PMID: 16865578 DOI: 10.1007/s10620-006-8016-9

RE-AIMS 7/22/2020 3:25:35 PM


67. Gallegos-Orozco JF, Arenas JI, Vargas HE, Kibler KV, Wilkinson JK, Nowicki M, Radkowski M, Nasseri J, Rakela J, Laskus T. Selection of different 5' untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection. J Viral Hepat. 2006 Jul; 13 (7):489-98 PMID: 16792543 PMCID: 0 DOI: 10.1111/j.1365-2893.2006.00724.x

68. Vargas HE. A difficult case of primary sclerosing cholangitis. Liver Transpl. 2006 Nov; 12(11 Suppl 2):S65-7. PMID: 17051564 DOI: 10.1002/lt.20951

69. Cheruvattath R, Orrego M, Gautam M, Byrne T, Alam S, Voltchenok M, Edwin M, Wilkens J, Williams JW, Vargas HE. Vitamin A toxicity: when one a day doesn't keep the doctor away. Liver Transpl. 2006 Dec; 12: (12)1888-91. PMID: 17133567 DOI: 10.1002/lt.21007

70. Gallegos-Orozco JF, Vargas HE. Should antihepatitis B virus core positive or antihepatitis C virus core positive subjects be accepted as organ donors for liver transplantation? J Clin Gastroenterol. 2007 Jan; 41(1):66-74. PMID: 17198068 DOI: 10.1097/01.mcg.0000225636.60404.bf

71. Cheruvattath R, Rosati MJ, Gautam M, Vargas HE, Rakela J, Balan V. Pegylated interferon and ribavirin failures: is retreatment an option? Dig Dis Sci. 2007 Mar; 52 (3):732-6 PMID: 17253142 DOI: 10.1007/s10620-006-9457-x

72. Werner T, Vargas HE, Chalasani N. Macro-aspartate aminotransferase and monoclonal gammopathy: a review of two cases. Dig Dis Sci. 2007 May; 52 (5):1197-8 Epub 2007 Mar 15 PMID: 17357839 DOI: 10.1007/s10620-006-9555-9

73. Pasha SF, Harrison ME, Das A, Nguyen CC, Vargas HE, Balan V, Byrne TJ, Douglas DD, Mulligan DC. Endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplantation: outcomes after maximal stent therapy. Gastrointest Endosc. 2007 Jul; 66: (1)44-51. PMID: 17591473 DOI: 10.1016/j.gie.2007.02.017

74. McCashland T, Watt K, Lyden E, Adams L, Charlton M, Smith AD, McGuire BM, Biggins SW, Neff G, Burton JR Jr, Vargas H, Donovan J, Trotter J, Faust T. Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study. Liver Transpl. 2007 Sep; 13(9):1246-53. PMID: 17763405 DOI: 10.1002/lt.21322

75. Lee HR, Hurst RT, Vargas HE. Transient left ventricular apical ballooning syndrome (Takotsubo cardiomyopathy) following orthotopic liver transplantation. Liver Transpl. 2007 Sep; 13(9):1343-5. PMID: 17763390 DOI: 10.1002/lt.21169

76. Rodriguez-Luna H, Vargas HE. Portal vein thrombosis. Curr Treat Options Gastroenterol. 2007 Dec; 10 (6):435-43 PMID: 18221604 DOI: 10.1007/s11938-007-0043-x

77. de Franchis R, Eisen GM, Laine L, Fernandez-Urien I, Herrerias JM, Brown RD, Fisher L, Vargas HE, Vargo J, Thompson J, Eliakim R. Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. Hepatology. 2008 May; 47(5):1595-603. PMID: 18435461 DOI: 10.1002/hep.22227

78. Mekeel KL, Moss AA, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne TJ, Harrison ME, Rakela J, Mulligan DC. Living donor liver transplantation in polycystic liver disease. Liver Transpl. 2008 May; 14(5):680-3. PMID: 18433036 DOI: 10.1002/lt.21423

79. Umphrey LG, Hurst RT, Eleid MF, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP. Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. Liver Transpl. 2008 Jun; 14(6):886-92. PMID: 18508373 DOI: 10.1002/lt.21495

80. Carey EJ, Vargas HE, Douglas DD, Balan V, Byrne TJ, Harrison ME, Rakela J. Inpatient admissions for drug-induced liver injury: results from a single center. Dig Dis Sci. 2008 Jul; 53 (7):1977-82 Epub 2008 Apr 05 PMID: 18392678 DOI: 10.1007/s10620-008-0250-x

81. Gallegos-Orozco JF, Rakela J, Rosati MJ, Vargas HE, Balan V. Persistence of hepatitis C virus in peripheral blood mononuclear cells of sustained viral responders to pegylated interferon and ribavirin therapy. Dig Dis Sci. 2008 Sep; 53 (9):2564-8 Epub 2008 July 02 PMID: 18594984 DOI: 10.1007/s10620-008-0323-x

82. Gurudu SR, Vargas HE, Leighton JA. New frontiers in small-bowel imaging: the expanding technology of capsule endoscopy and its impact in clinical gastroenterology. Rev Gastroenterol Disord. 2008 Winter; 8(1):1-14. PMID: 18477965

RE-AIMS 7/22/2020 3:25:35 PM


83. Silva AC, Evans JM, McCullough AE, Jatoi MA, Vargas HE, Hara AK. MR imaging of hypervascular liver masses: a review of current techniques. Radiographics. 2009 Mar-Apr; 29(2):385-402. PMID: 19325055 DOI: 10.1148/rg.292085123

84. Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009 Jul; 93 (4):931-50, ix PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010

85. Singh V, Rudraraju M, Carey EJ, Byrne TJ, Douglas DD, Rakela J, Vargas HE. An unusual occurrence of giant cell hepatitis. Liver Transpl. 2009 Dec; 15(12):1888-90. PMID: 19938107 DOI: 10.1002/lt.21881

86. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, De Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transpl. 2009 Dec; 15(12):1872-81. PMID: 19938138 DOI: 10.1002/lt.21954

87. Eleid MF, Hurst RT, Vargas HE, Rakela J, Mulligan DC, Appleton CP. Short-term cardiac and noncardiac mortality following liver transplantation. J Transplant. 2010; 2010 Epub 2010 Aug 12 PMID: 20814597 PMCID: 2931376 DOI: 10.1155/2010/910165

88. Werner T, Aqel B, Balan V, Byrne T, Carey E, Douglas D, Heilman RL, Rakela J, Mekeel K, Reddy K, Vargas HE. Treatment of hepatitis C in renal transplantation candidates: a single-center experience. Transplantation. 2010 Aug 27; 90 (4):407-11 PMID: 20571469 DOI: 10.1097/TP.0b013e3181e72837

89. Carey EJ, Steidley DE, Aqel BA, Byrne TJ, Mekeel KL, Rakela J, Vargas HE, Douglas DD. Six-minute walk distance predicts mortality in liver transplant candidates. Liver Transpl. 2010 Dec; 16(12):1373-8. PMID: 21117246 DOI: 10.1002/lt.22167

90. Martin KA, Bostwick JM, Vargas HE. Liver transplant case report: Transgenderism and liver transplantation. International Journal of Transgenderism. 2011 Oct; 13(1):45-9.

91. Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403. PMID: 21850690 DOI: 10.1002/lt.22417

92. Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Rakela J, Vargas HE, Moss AA, Mulligan DC, Reddy KS, Chakkera HA. Pretransplant fasting glucose predicts new-onset diabetes after liver transplantation. J Transplant. 2012; 2012:614781 Epub 2012 Jan 29 PMID: 22461975 PMCID: 3306927 DOI: 10.1155/2012/614781

93. Lalezari J, Asmuth D, Casiro A, Vargas H, Lawrence S, Dubuc-Patrick G, Chen J, McCarville J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai J, Mayerse D. Short-term monotherapy with IDX184, a liver-targeted nucleotide polymerase inhibitor, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2012; 56(12):6372-8. PMID: 23070151 PMCID: 3497200

94. Gordon FD, Kwo P, Ghalib R, Crippin J, Vargas HE, Brown KA, Schiano T, Chaudhri E, Pedicone LD, Brown RS Jr. Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol. 2012 Sep; 46(8):700-8. PMID: 22739223 DOI: 10.1097/MCG.0b013e31825833be

95. Hsieh TH, Mekeel KL, Crowell MD, Nguyen CC, Das A, Aqel BA, Carey EJ, Byrne TJ, Vargas HE, Douglas DD, Mulligan DC, Harrison ME. Endoscopic treatment of anastomotic biliary strictures after living donor liver transplantation: outcomes after maximal stent therapy. Gastrointest Endosc. 2013 Jan; 77(1):47-54 Epub 2012 Oct 11. PMID: 23062758 DOI: 10.1016/j.gie.2012.08.034

96. Yadav AD, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, Mulligan DC, Rakela J, Vargas HE, Carey EJ. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. J Transplant. 2013; 2013:269096 Epub 2013 Sept 24 PMID: 24205434 PMCID: 3800575 DOI: 10.1155/2013/269096

97. Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, Harrison ME, Rakela J, Aqel BA. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013 Jun; 58 (6):1776-80 Epub 2013 Jan 12 PMID: 23314858 DOI: 10.1007/s10620-012-2548-y

RE-AIMS 7/22/2020 3:25:35 PM


98. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013 Jul; 19 (7):690-700 Epub 2013 June 03 PMID: 23696372 DOI: 10.1002/lt.23669

99. Unzueta A, Vargas HE. Nonsteroidal anti-inflammatory drug-induced hepatoxicity. Clin Liver Dis. 2013 Nov; 17: (4)643-56, ix. PMID: 24099022 DOI: 10.1016/j.cld.2013.07.009

100.

Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, Brown KA, Nashan B, Rostaing L, Meadows-Shropshire S, Agarwal M, Harler MB, García-Valdecasas JC. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant. 2014; 14(8):1817-27. PMID: 25041339 PMCID: 4140547

101.

Manns MP, Vierling JM, Bacon BR, Bruno S, Shibolet O, Baruch Y, Marcellin P, Caro L, Howe AYM, Fandozzi C, Gress J, Gilbert CL, Shaw PM, Cooreman MP, Robertson MN, Hwang P, Dutko FJ, Wahl J, Mobashery N, Investigators. The Combination of MK-5172, Peginterferon, and Ribavirin is Effective in Treatment-Naive Patients with Hepatitis C Virus Genotype 1 Infection without Cirrhosis. Gastroenterology. 2014; 147(2):366-76.

102.

Corey RL, Whitaker MD, Crowell MD, Keddis MT, Aqel B, Balan V, Byrne T, Carey E, Douglas DD, Harrison ME, Vargas HE, Rakela J. Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. Clin Transplant. 2014 May; 28 (5):579-84 Epub 2014 Apr 21 PMID: 24628047 DOI: 10.1111/ctr.12351

103.

Ratuapli SK, Vargas HE. Colonoscopy in liver disease. Clin Liver Dis (Hoboken). 2014 Nov; 4 (5):109-112 Epub 2014 Dec 09 PMID: 30992934 PMCID: 6448747 DOI: 10.1002/cld.433

104.

Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, Hillson J, Horga MA, Jacobson IM, Jeffers L, Kowdley KV, Lawitz E, Lueth S, Rodriguez-Torres M, Rustgi V, Shemanski L, Shiffman ML, Srinivasan S, Vargas HE, Vierling JM, Xu D, Lopez-Talavera JC, Zeuzem S, EMERGE study group. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol. 2014 Dec; 61 (6):1238-46 Epub 2014 July 24 PMID: 25064437 DOI: 10.1016/j.jhep.2014.07.022

105.

Terrault NA, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins TM. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014 Dec; 61 (6):1253-9 Epub 2014 July 15 PMID: 25048952 DOI: 10.1016/j.jhep.2014.07.007

106.

Gallegos-Orozco JF, Silva AC, Batheja MJ, Chang YH, Hansen KL, Lam-Himlin D, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan DC, Silva AM, Rakela J, Vargas HE. Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Abdom Imaging. 2014 Dec 02. PMID: 25445158 DOI: 10.1007/s00261-014-0310-y

107.

Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R Jr, Gordon F, Levitsky J, Terrault NA, Burton JR Jr, Xie W, Setze C, Badri P, Pilot-Matias T, Vilchez RA, Forns X. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Dec 18; 371(25):2375-82. Epub 2014 Nov 11. PMID: 25386767 DOI: 10.1056/NEJMoa1408921

108.

Gordon SC, Muir AJ, Lim JK, Pearlman B, Argo CK, Ramani A, Maliakkal B, Alam I, Stewart TG, Vainorius M, Peter J, Nelson DR, Fried MW, Reddy KR, on behalf of the HCV-TARGET study group. Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET. Journal of Hepatology. 2015; 62:286-93.

109.

Yadav A, Chang YH, Carpenter S, Silva AC, Rakela J, Aqel BA, Byrne TJ, Douglas DD, Vargas HE, Carey EJ. Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. Clin Transplant. 2015 Feb; 29(2):134-41. Epub 2015 Jan 09. PMID: 25430554 DOI: 10.1111/ctr.12493

110.

Yadav A, Vargas HE. Care of the patient with cirrhosis. Clin Liver Dis (Hoboken). 2015 Apr; 5 (4):100-104 Epub 2015 May 07 PMID: 31040961 PMCID: 6490512 DOI: 10.1002/cld.462

RE-AIMS 7/22/2020 3:25:35 PM


111.

Batheja M, Vargas H, Silva AM, Walker F, Chang YH, De Petris G, Silva AC. Magnetic resonance elastography (MRE) in assessing hepatic fibrosis: performance in a cohort of patients with histological data. Abdom Imaging. 2015 Apr; 40: (4)760-5. PMID: 25542217 DOI: 10.1007/s00261-014-0321-8

112.

Aqel BA, Vargas HE. Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. Curr Opin Organ Transplant. 2015 Jun; 20 (3):259-66 PMID: 25944237 DOI: 10.1097/MOT.0000000000000195

113.

Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny AP. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015 Jun; 61(6):1880-6. Epub 2015 Apr 27. PMID: 25722203 DOI: 10.1002/hep.27770

114.

Horsley-Silva JL, Vargas HE. Gastrointestinal endoscopy in the cirrhotic patient. Expert Rev Gastroenterol Hepatol. 2015 Jul; 9 (7):1005-13 Epub 2015 May 12 PMID: 25967459 DOI: 10.1586/17474124.2015.1044978

115.

Chung RT, Davis GL, Jensen DM, Masur H, Saag MS, Thomas DL, Aronsohn AI, Charlton MR, Feld JJ, Fontana RJ, Ghany MG, Godofsky EW, Graham CS, Kim AY, Kiser JJ, Kottilil S, Marks KM, Martin P, Mitruka K, Morgan TR, Naggie S, Raymond D, Reau NS, Schooley RT, Sherman KE, Sulkowski MS, Vargas HE, Ward JW, Wyles DL. Hepatitis c guidance: aasld-idsa recommendations for testing, managing, and treating adults infected with hepatitis c virus. Hepatology. 2015 Sep; 62(3):932-54. PMID: 26111063

116.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N, SOLAR-1 Investigators. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149 (3):649-59 Epub 2015 May 15 PMID: 25985734 DOI: 10.1053/j.gastro.2015.05.010

117.

Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, Murphy JL, Ryland K, Keaveny AP, McLemore R, Vargas HE. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015 Oct; 62 (4):1004-12 Epub 2015 Aug 07 PMID: 26096332 DOI: 10.1002/hep.27937

118.

Horsley-Silva JL, Dow EN, Menias CO, Smith ML, Carballido EM, Lindor KD, Vargas HE. Docetaxel Induced Sclerosing Cholangitis. Dig Dis Sci. 2015 Oct 26. [Epub ahead of print] PMID: 26501143 DOI: 10.1007/s10620-015-3914-3

119.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Darling JM, Feld JJ, Brown RS, Frazier LM, Stewart TG, Fried MW, Nelson DR, Jacobson IM, HCV-TARGET Study Group. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. Gastroenterology. 2016 Feb; 150 (2):419-29 Epub 2015 Oct 21 PMID: 26497081 PMCID: 4727992 DOI: 10.1053/j.gastro.2015.10.013

120.

Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas H, Thacker LR, O'Leary JG, North American Consortium for the Study of End-Stage Liver Disease. The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. Hepatology. 2016 Jul; 64 (1):200-8 Epub 2016 Feb 19 PMID: 26690389 PMCID: 4700508 DOI: 10.1002/hep.28414

121.

Kahn A, Reynolds JA, Chakkera HA, Aqel BA, Byrne TJ, Douglas DD, Moss AA, Vargas HE, Carey EJ. Prospective Analysis of Metabolic Parameters in the Detection of Diabetes and Metabolic Syndrome in Liver Transplant Recipients. Metab Syndr Relat Disord. 2016 Aug; 14 (6):305-10 Epub 2016 May 10 PMID: 27164306 DOI: 10.1089/met.2015.0162

122.

Horsley-Silva JL, Vargas HE. New Therapies for Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y). 2017 Jan; 13 (1):22-31 PMID: 28420944 PMCID: 5390323

123.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM, Vargas HE, Lai J, Thacker LR, Reddy KR. Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. Clin Gastroenterol Hepatol. 2017 Apr; 15 (4):565-574.e4 Epub 2016 Oct 05 PMID: 27720916 DOI: 10.1016/j.cgh.2016.09.157

RE-AIMS 7/22/2020 3:25:35 PM


124.

Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MD, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ, Vapreotide Study Group. Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage: Analysis of a US Multicenter Prospective Study. J Clin Gastroenterol. 2017 May/Jun; 51 (5):446-453 PMID: 27779613 PMCID: 5403609 DOI: 10.1097/MCG.0000000000000733

125.

Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Mullhaupt B. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Ann Hepatol. 2017 May - Jun; 16 (3):375-381 PMID: 28425407 DOI: 10.5604/16652681.1235480

126.

Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS Jr, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Mullhaupt B. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Ann Hepatol. 2017 May - Jun; 16 (3):375-381 PMID: 31153438 DOI: 10.5604/01.3001.0009.8592

127.

Sanyal AJ, Boyer TD, Frederick RT, Wong F, Rossaro L, Araya V, Vargas HE, Reddy KR, Pappas SC, Teuber P, Escalante S, Jamil K. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies. Aliment Pharmacol Ther. 2017 Jun; 45 (11):1390-1402 Epub 2017 Mar 29 PMID: 28370090 PMCID: 5434950 DOI: 10.1111/apt.14052

128.

Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Fallon MB, Biggins SW, Subramanian RM, Thuluvath PJ, Kamath PS, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj JS. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes. Am J Gastroenterol. 2017 Jul; 112 (7):1103-1110 Epub 2017 Apr 25 PMID: 28440305 DOI: 10.1038/ajg.2017.122

129.

Lok AS, Chung RT, Vargas HE, Kim AY, Naggie S, Powderly WG. Comments on cochrane review on direct-acting antivirals for hepatitis C. Hepatology. 2017 Oct; 66 (4):1016-1019 Epub 2017 Aug 26 PMID: 28714142 DOI: 10.1002/hep.29366

130.

Perez ST, Arring NM, Vargas HE, Corbett BM, Ehler S, Beck GL, Temkit M, Aqel BA, Rakela J. Improving hepatitis vaccination series completion in patients awaiting liver transplantation. Journal for Nurse Practitioners. 2017; 13 (9):e441-4 DOI: 10.1016

131.

Powderly WG, Naggie S, Kim AY, Vargas HE, Chung RT, Lok AS. IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. Clin Infect Dis 2017 Nov 13; 65 (11):1773-1775 PMID: 29020156 DOI: 10.1093/cid/cix620

132.

Lok AS, Chung RT, Vargas HE, Kim AY, Naggie S, Powderly WG. Benefits of Direct-Acting Antivirals for Hepatitis C. Ann Intern Med. 2017 Dec 5; 167 (11):812-813 Epub 2017 Oct 17 PMID: 29049502 DOI: 10.7326/M17-1876

133.

Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourliere M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018 Jan 25; 378 (4):354-369 PMID: 29365309 DOI: 10.1056/NEJMoa1702417

134.

Bajaj JS, Reddy RK, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Fallon M, Maliakkal B, Lai J, Vargas HE, Subramanian RM, Thuluvath P, Thacker LR, O'Leary JG. Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. Am J Gastroenterol. 2018 Apr; 113 (4):556-563 Epub 2017 Dec 19 PMID: 29257141 DOI: 10.1038/ajg.2017.471

135.

Rubin RA, Russo MW, Brown KA, Fontana RJ, Levitsky J, Vargas H, Yoshida EM, Brown RS Jr. Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Exp Clin Transplant. 2018 Apr; 16 (2):182-190 Epub 2016 Nov 18 PMID: 27855589 DOI: 10.6002/ect.2016.0251

RE-AIMS 7/22/2020 3:25:35 PM


136.

O'Leary JG, Reddy KR, Garcia-Tsao G, Biggins SW, Wong F, Fallon MB, Subramanian RM, Kamath PS, Thuluvath P, Vargas HE, Maliakkal B, Tandon P, Lai J, Thacker LR, Bajaj JS. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology. 2018 Jun; 67 (6):2367-2374 Epub 2018 Apr 19 PMID: 29315693 DOI: 10.1002/hep.29773

137.

Chascsa DM, Vargas HE. The gastroenterologist's guide to management of the post-liver transplant patient. Am J Gastroenterol. 2018 Jun; 113 (6):819-828 Epub 2018 May 11 PMID: 29748558 DOI: 10.1038/s41395-018-0049-0

138.

Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Zhang N, Pungpapong S. Multicenter Experience using Ledipasvir/Sofosbuvir +/- RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Ann Hepatol. 2018 Aug 24; 17 (5):815-821 PMID: 30145562 DOI: 10.5604/01.3001.0012.3142

139.

Aqel B, Leise M, Vargas HE, Watt KD, Keaveny AP, Zhang N, Pungpapong S. Multicenter Experience using Ledipasvir/Sofosbuvir +/- RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Ann Hepatol. 2018 Sep - Oct; 17 (5):815-821 PMID: 31104796 DOI: 10.5604/01.3001.0012.3142

140.

Bajaj JS, Tandon P, O'Leary JG, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai JC, Fallon M, Thuluvath P, Vargas HE, Subramanian RM, Thacker LR, Reddy RK. The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. Am J Gastroenterol. 2018 Sep; 113 (9):1339 Epub 2018 June 08 PMID: 29880972 DOI: 10.1038/s41395-018-0119-3

141.

Bajaj JS, Moreau R, Kamath PS, Vargas HE, Arroyo V, Reddy KR, Szabo G, Tandon P, Olson J, Karvellas C, Gustot T, Lai JC, Wong F. Acute-on-Chronic Liver Failure: Getting Ready for Prime Time? Hepatology. 2018 Oct; 68 (4):1621-1632 Epub 2018 Sept 22 PMID: 29689120 DOI: 10.1002/hep.30056

142.

Chascsa DM, Mousa OY, Chascsa DM, Mousa OY, Pungpapong S, Zhang N, Chervenak A, Zhang N, Chervenak A, Nidamanuri S, Rodriguez E, Franco D, Ryland K, Ryland K, Keaveny AP, Huskey JL, Smith M, Huskey JL, Smith M, Reddy KS, Taner CB, Vargas HE, Aqel BA. Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. Am J Transplant. 2018 Oct; 18 (10):2559-2565 Epub 2018 June 08 PMID: 29758123 DOI: 10.1111/ajt.14931

143.

Laique SN, Vargas HE. Hepatitis C Virus: No Longer a Barrier to Oncology Care. Am J Gastroenterol 2019 Feb; 114 (2):207-208 PMID: 30676362 DOI: 10.14309/ajg.0000000000000095

144.

Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2019 Mar; 17 (4):756-765.e3 Epub 2018 July 20 PMID: 30036646 DOI: 10.1016/j.cgh.2018.07.022

145.

O'Leary JG, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Reddy KR. Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience. Liver Transpl. 2019 Apr; 25 (4):571-579 Epub 2019 Mar 24 PMID: 30724010 DOI: 10.1002/lt.25426

146.

Bajaj JS, Tandon P, O'Leary JG, Wong F, Biggins SW, Garcia-Tsao G, Kamath PS, Maliakkal B, Fallon MB, Lai JC, Thuluvath PJ, Vargas HE, Subramanian RM, Thacker LR, Reddy KR. Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. Am J Gastroenterol. 2019 Apr; 114 (4):599-606 PMID: 30694868 PMCID: 6450703 DOI: 10.14309/ajg.0000000000000044

147.

Wong F, Reddy KR, O'Leary JG, Tandon P, Biggins SW, Garcia-Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transpl. 2019 Jun; 25 (6):870-880 Epub 2019 Apr 25 PMID: 30908855 DOI: 10.1002/lt.25454

148.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther. 2019 Jun; 49 (12):1518-1527 Epub 2019 Apr 29 PMID: 31032966 PMCID: 6538445 DOI: 10.1111/apt.15265

RE-AIMS 7/22/2020 3:25:35 PM


149.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Garcia-Tsao G, Kamath PS, Biggins SW, Lai JC, Vargas HE, Maliakkal B, Fallon MB, Thuluvath PJ, Subramanian RM, Thacker LR, Reddy KR. Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. Am J Gastroenterol. 2019 Jul; 114 (7):1091-1100 PMID: 31180922 PMCID: 6610719 DOI: 10.14309/ajg.0000000000000280

150.

Kawut SM, Ellenberg SS, Krowka MJ, Goldberg D, Vargas H, Koch D, Sharkoski T, Al-Naamani N, Fox A, Brown R, Levitsky J, Oh JK, Lin G, Song N, Mottram C, Doyle MF, Kaplan DE, Gupta S, Fallon MB. Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Liver Transpl. 2019 Aug; 25 (8):1155-1164 Epub 2019 May 30 PMID: 30816637 PMCID: 6910867 DOI: 10.1002/lt.25438

151.

Arab JP, Sehrawat TS, Simonetto DA, Verma VK, Feng D, Tang T, Dreyer K, Yan X, Daley WL, Sanyal A, Chalasani N, Radaeva S, Yang L, Vargas H, Ibacache M, Gao B, Gores GJ, Malhi H, Kamath PS, Shah VH. An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. Hepatology. 2019 Nov 27 [Epub ahead of print] PMID: 31774566 PMCID: 7250715 DOI: 10.1002/hep.31046

152.

O'Leary JG, Tandon P, Reddy KR, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas HE, Thuluvath P, Subramanian R, Thacker LR, Bajaj JS. Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. Dig Dis Sci. 2020 Mar 7 Epub 2020 Mar 07 PMID: 32146602 DOI: 10.1007/s10620-020-06168-8

153.

Bajaj JS, Duarte-Rojo A, Xie JJ, Acharya C, Wade J, Robles C, Thacker LR, Flud C, Fagan A, Garcia-Saenz-de-Sicilia M, White MB, Kelly M, Nguyen V, Gavis EA, Vargas HE. Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020 Mar 20 [Epub ahead of print] PMID: 32205222 DOI: 10.1016/j.cgh.2020.03.033

154.

Mahdi L, Kahn A, Dhamija R, Vargas HE. Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy. ACG Case Rep J. 2020 Apr; 7 (4):e00375 Epub 2020 Apr 07 PMID: 32548202 PMCID: 7224721 DOI: 10.14309/crj.0000000000000375

155.

Rodriguez EA, Perez R, Zhang N, Lim ES, Miller C, Schwartz MA, McGirr AJ, Srinivasan A, Hewitt W, Silva AC, Rakela J, Vargas HE. Clinical Outcomes of Portosystemic Shunts on the Outcome of Liver Transplantation. Liver Transpl. 2020 May; 26 (5):693-701 Epub 2020 Mar 12 PMID: 31872966 DOI: 10.1002/lt.25710

156.

Yu NY, DeWees TA, Alam M, Ochoa SA, Mangold AR, Steidley DE, Vargas HE, Golafshar MA, Schild SE, Halyard MY, Patel SH. Risk of Recurrence and 10-Year Outcomes in Surgically Treated Nonmelanoma Skin Cancer in Cardiac and Liver Transplant Recipients. Am J Clin Oncol. 2020 May; 43 (5):366-370 PMID: 32217856 DOI: 10.1097/COC.0000000000000677

157.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2020 May 8 Epub 2020 May 08 PMID: 32389884 DOI: 10.1016/j.cgh.2020.04.081

158.

Bajaj JS, Reddy KR, O'Leary JG, Vargas HE, Lai JC, Kamath PS, Tandon P, Wong F, Subramanian RM, Thuluvath P, Fagan A, White MB, Gavis EA, Sehrawat T, Rodriguez RR, Thacker LR, Sikaroodi M, Garcia-Tsao G, Gillevet PM. Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute on Chronic Liver Failure and Death in Patients With Cirrhosis. Gastroenterology. 2020 Jul 17 Epub 2020 July 17 PMID: 32687928 DOI: 10.1053/j.gastro.2020.07.019

Books

1. Talley NJ, Lindor KD, Vargas HE. Practical gastroenterology and hepatology. Liver and biliary disease. Chichester; Hoboken: Wiley-Blackwell; 2010. (Practical Gastroenterology and Hepatology.).

RE-AIMS 7/22/2020 3:25:35 PM


Editorials

1. Rakela J, Vargas H, Arenas J. Is D-penicillamine useful in fulminat Wilson's disease? Liver Transpl. 2002 May; 8(5):502-3.

2. McCaughan GW, Laskus T, Vargas HE. Hepatitis C virus quasispecies: Misunderstood and mistreated? Liver Transpl. 2003 Oct; 9(10):1048-52.

3. Vargas H. Introducing T.H.E. corner. Liver Transpl. 2007 Nov; 13(11):1479.

4. Vargas HE. Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST. Hepatology 2016 Aug; 64 (2):330-2 Epub 2016 Apr 18

Book Chapters

1. Doria C, Giraldo M, Bueno J, Mazariegos G, Vargas H, Kocoshis S, Marino I, Demetris A, Fung JJ, Starzl TE, Reyes J, Abu-Elmagd. Intestinal Transplantation: Current Status and Latest Developments. In: Surgical Technology International 1999.

2. Vargas H, Silverman W. Oral Mucositis And Gastrointestinal Complications. In: In Hematopoietic Stem Cell Therapy. Philadelphia: 2000.

3. Boyer TD, Vargas HE. Transjugular intrahepatic portasystemic shunts. In: Schiff ER, Sorrell MF, Madrey WC. Schiff's Diseases of the Liver. 9th Ed ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2002.

4. Vargas HE, Boyer TD. Hepatic venous outflow obstruction: Budd-Chiari syndrome and veno-occlusive disease. In:. Sanyal AJ, Shah VH, editors. Portal hypertension: pathobiology, evaluation, and treatment. Totowa: Humana Press; 2005. (Clinical Gastroenterology.). p. 433-53.

5. Sharma P, Vargas HE, Rakela J. Monitoring and care of the patient before liver transplantation. In:. Busuttil RW, Klintmalm GB, editors. Transplantation of the liver. 2nd Edition. Philadelphia: Elsevier Saunders; 2005. p. 473-89.

6. Rodriguez-Luna H, Vargas HE. Portal Vein Thrombosis. In: Boyer TD, Wright T, Mans M. Hepatology: A Textbook of Liver Disease. 4th ed. Philadelphia, PA: Saunders; 2005.

7. Rodriguez-Luna H, Vargas HE. Portal and splenic vein thrombosis. In:. Boyer TC, Wright TL, Manns MP, editors. Zakim and Boyer's hepatology: a textbook of liver disease. 5th Edition. Volume 2. Philadelphia: Saunders Elsevier; 2006. p. 905-14.

8. Rodriguez-Luna H, Vargas HE. Métodos de Apoyo a la Función Hepática. In: Berenguer & Parrilla. Transplante Hepático 2nd ed. Barcelona Spain: Elsevier; 2007.

9. Mai A, Vargas HE. Neurological problems seen during the management of the patient with viral hepatitis. In:. Biller J, editor. The interface of neurology & internal medicine. Philadelphia: Wolters Kluwer Health/Lippincott Wiliams & Wilkins; 2008. p. 265-73.

10. Batheja MJ, Vargas HE. Assessment of abnormal liver injury tests. In:. Talley NJ; Lindor KD; Vargas HE editor. Practical gastroenterology and hepatology. Liver and biliary disease. Chichester; Hoboken: Wiley-Blackwell; 2010. (Practical Gastroenterology and Hepatology.). p. 32-7.

11. Vargas HE. Endoscopic techniques in management of the liver and biliary tree: upper gastrointestinal endoscopy. In: Talley NJ; Lindor KD; Vargas HE. Practical gastroenterology and hepatology. Liver and biliary disease. Chichester; Hoboken: Wiley-Blackwell; 2010. p. 55-60. (Practical Gastroenterology and Hepatology.)

12. Curtis KK, Slack JL, Vargas HE. Hepatic complications of bone marrow transplantation. In:. Talley NJ; Lindor KD; Vargas HE editor. Practical gastroenterology and hepatology. Liver and biliary disease. Chichester; Hoboken: Wiley-Blackwell; 2010. (Practical Gastroenterology and Hepatology.). p. 275-87.

13. Gallegos-Orozco JF, Vargas HE. Drug-induced, granulomatous, and other inflammatory hepatic diseases. In:. DiBaise JK editor. Gastroenterology and hepatology board review. 3rd Edition. New York: McGraw-Hill Medical; 2012. (Pearls of Wisdom.). p. 389-98.

14. Carey EJ, Rakela J, Vargas HE. Monitoring and care. In:. Transplantation of the liver. Third Edition. 2015. p. 478-93.

RE-AIMS 7/22/2020 3:25:35 PM


Commentaries

1. Vargas HE, Krahn L. The transplantation candidate with alcohol misuse: the selection minefield. Liver Transpl. 2008 Nov; 14(11):1559-60. PMID:18975287 DOI:10.1002/lt.21604

Abstracts

1. Scott VL, Nelson F, Dewolf AM, Paradis I, Ziady G, Kang Y, Vargas H, Rakela J, Fung J. Hepatopulmonary syndrome: a reversible disease by orthotopic liver transplantation. Gastroenterology. 1995; 108(4 Suppl):A1165.

2. Wang LF, Radkowski M, Laskus T, Vargas H, Cianciara J, Poutous T, Rakela J. Comparison of hepatitis B virus core promoter sequences in peripheral blood mononuclear cells and serum from patients with hepatitis B. Hepatology. 1996; 24(4 Part 2):409A.

3. Vargas H, Wang L, Laskus T, Fung J, Rakela J. HCV genotypes in Middle Eastern end-stage liver disease patients and clinical outcome of liver transplantation. Gastroenterology. 1996; 110(4 Suppl):A1352.

4. Laskus T, Rakela J, Wang LF, Nowicki M, Vargas H, Adjukiewicz A. Hepatitis B virus (HBV) core promoter and precore sequences in African patients with hepatocellular carcinoma. Gastroenterology. 1996; 110(4 Suppl):A1245.

5. Poutous A, Vargas H, Laskus T, Wang L, Radkowski M, Lee R, Demetris J, Gayowski T, Marino J, Singh N, Dodson F, Fung J, Rakela J. Hepatitis G virus infection in HCV-positive liver transplant recipients. Hepatology. 1996; 24(4 Part 2):420A.

6. Vargas H, Wang L, Laskus T, Lee R, Fung J, Rakela J. Influence of HCV genotypes and HLA matching on the recurrence of hepatitis in patients receiving liver transplantation for HCV induced end- stage liver disease. Gastroenterology. 1996; 110(4 Suppl):A1353.

7. Wang LF, Laskus T, Rakela J, Vargas H, Radkowski M, Cianciara J. Single-strand conformation polymorphism (SSCP) study of hepatitis B virus in serum and peripheral blood mononuclear cells. Gastroenterology. 1996; 110(4 Suppl):A1357.

8. Laskus T, Wang LF, Radkowski M, Vargas H, Poutous T, Rakela J. Substitutions at positions 1762 and 1764 neither change the activity of the HBV core promoter nor influence mRNA synthesis in vitro. Hepatology. 1996; 24(4 Part 2):408A.

9. Vargas H, Wang L, Laskus T, Poutos A, Lee R, Demetris J, Gayowski T, Marino I, Singh N, Dodson F, Casavilla A, Fung J, Rakela J. HCV genotypes: a report on HCV genotype influence on the outcome of liver transplantation for HCV related end-stage liver disease. Liver Transpl Surg. 1997; 3(5):C-42.

10. Laskus T, Radkowski M, Wang LF, Cianciara J, Vargas H, Rakela J. Hepatitis C virus negative strand is not detected in peripheral blood mononuclear cells and viral sequences are identical to those in serum: a case against extrahepatic replication. Hepatology. 1997; 26(4 Part 2):546A.

11. Laskus T, Wang LF, Radkowski M, Jang SJ, Vargas H, Dodson F, Fung J, Rakela J. Hepatitis G virus (HGV) infection in American patients with cryptogenic cirrhosis: no evidence for liver replication. Hepatology. 1997; 26(4 Part 2):152A.

12. Araya V, Vinayek R, Aleong R, Lee R, Varges H, Lombardero M, Laskus T, Wang L, Dobson F, Fung J, Rakela J. Natural histological progression of liver disease in patients with hepatitis C after liver transplantation. Hepatology. 1997; 26(4 Part 2):154A.

13. Vargas HE, Laskus T, Wang LF, Radkowski M, Dodson F, Fung JJ, Rakela J. Outcome of liver transplantation of HCV positive grafts in HCV infected recipients. Hepatology. 1997; 26(4 Part 2):154A.

14. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Analysis of hepatitis C quasi-species recovered from peripheral blood mononuclear cells and various tissues from patients infected with human immunodeficiency virus type 1: correlation with extrahepatic viral replication. Hepatology. 1998; 28(4 pt. 2):687A.

15. Taniguchi M, Vargas HE, Laskus T, Nalesnik M, Dodson F, Iwatsuki S, Fung JJ, Rakela J. De novo hepatitis B virus related hepatocellular carcinoma after liver transplantation: a report of three cases. Hepatology. 1998 Oct; 28(4 Part 2):345A.

RE-AIMS 7/22/2020 3:25:35 PM


16. Dodson SF, Vargas H, Shakil O, Balan V, Bonham A, Rakela J, Fung JJ. Final analysis of ribavirin and alpha-interferon for the treatment of hepatitis C infection after liver transplantation. Hepatology. 1998 Oct; 28(4 Part 2):262A.

17. Taniguchi M, Vargas HE, Wang L, Laskus T, Lee R, Demetris J, Gayowski T, Singh N, Dodson F, Fung J, Rakela J. Hepatitis C virus genotype and hepatocellular carcinoma: a Pittsburgh experience. Hepatology. 1998 Oct; 28(4 Part 2):221A.

18. Taniguchi M, Shakil AO, Vargas H, Laskus T, Demetris AJ, Gayowski T, Dodson SF, Fung JJ, Rakela J. Virological outcome of hepatitis B and C dual infection after liver transplantation: effect of hepatitis D co-infection. Hepatology. 1998 Oct; 28(4 Part 2):221A.

19. Balan V, Starzl TE, Dodson FS, Vargas HE, Shakil AO, Rosati M, Fung JJ, Rakela J. Long Term Follow-Up Of Lamivudine Therapy For Hepatitis B Before And After Liver Transplantation: Clinical Implication Of Development Of The YMDD Mutant. Hepatology. 1999; 30:741.

20. Vargas HE, Rosenblatt ML, Dodson F, Fung J, Rakela J. Natural History Of Barretts Esophagus In Orthotopic Liver Transplant Recipients. Hepatology. 1999; 30(4):2011.

21. Siqueira E, Martin JA, Vargas H, Minteer L, Slivka A. Prospective evaluation of a new metal stent for treating malignant biliary obstruction. Gastrointest Endosc. 1999; 49(4 pt. 2):AB236.

22. Rosenblatt ML, Francis FF, Dodson SF, Fung JJ, Rakela J, Vargas HE. Screening colonoscopy in evaluation of elective orthotopic liver transplantation (OLTX) in two age populations. Gastroenterology. 1999; 116(4 (pt.2)):A523.

23. Shah RJ, Margulies C, Rakela J, Schoen R, Vargas H, Slivka A. The incidence of colonic adenoma in patients undergoing evaluation for liver transplantation. Gastrointest Endosc. 1999; 49(4 pt. 2):AB68.

24. Khalid A, Demetris AJ, Balan V, Vargas HE. Case of Wilson's Disease and PBC Overlap. Hepatology. 2000; 32(4):1407 Part2.

25. Ahmad J, Shakil AO, Vargas HE, Fung JJ, Dodson SF. Comparison Of Alpha-Interferon Alone And Alpha-Interferon And Ribavirin For The Treatment Of Recurrent Hepatitis C After Liver Transplantation. Gastroenterology. 2000; 118(4):3732 Part 1 Supp 2.

26. Shakil AO, Vargas H, Gartner K, Downey K. Risk Factors And Disease Severity Among US War Veterans With Chronic Hepatitis C. Hepatology. 2000; 32(4):482 Part 2.

27. Vargas HE, Shakil O, Dzubinski L, Kapil, C, Francis F, Beringer K, Balan V, Rakela J. Treatment Of HCV Infection In An Academic Medical Center: The Experience With Interferon/Ribavirin. Hepatology. 2000; 4(Part 2):1628.

28. Ahmad J, Dodson SF, Balan V, Vargas HE, Fung JJ, Shakil AO. Adefovir Dipivoxil Suppresses Lamivudine Resistant Hepatitis B Virus In Liver Transplant Recipients. Hepatology. 2000 Oct 2; 32(4 part 2):522.

29. Khalid A, Ahmad J, Demetris AJ, Balan V, Vargas HE. Case Of Wilson’s Disease And PBC Overlap. Am J. 2001; Gastroenterol(9 Suppl):96.

30. Yousfi MM, Douglas DD, Rakela J, Savage WT, Mulligan DC, Harrison ME, Vargas HE, Eberhard K, Moss AA, Balan V. Increased prevalence of osteoporosis in patients with end-stage liver disease secondary to hepatitis C infection and alcohol. Gastroenterology. 2001 Apr; 120(5 Suppl 1):A.378.

31. Joya-Vazquez PP, Dodson FS, Dvorchik I, Gray E, Chesky A, Demetris AJ, Shakil O, Fung JJ, Vargas HE. The impact of anti-hepatitis BC positive grafts on the outcome of liver transplantation for HBV-related cirrhosis. (Abstract 52). Liver Transpl. 2001 Jun; 7(6):C-13.

32. Khalid A, Finkelstein S, Ahmad J, Imtiaz M, Shakil OA, Swalsky PA, Dodson FS, Fung JJ, Rakela J, Demetris AJ, Vargas HE. Alpha-1 antitrypsin genotypes in cirrhotic livers with pas-D(+) glubules:coexistence with other liver disease and outcome after liver transplant (OLTX) Am J Gastroenterol. 2001 Sep;96: (9 Suppl 1)

33. Savage WT III, Blair JE, Yousfi MM, Smilack JD, Nguyen BD, Post DJ, Balan V, Harrison ME, Vargas H, Douglas DD, Olden KW, Moss AA, Mulligan DC, Rakela J. Fungal brain abscess secondary to scedosporium aspiospermum infection after orthotopic liver transplantation (OLT). (Abstract 772). Am J Gastroenterol. 2001 Sep; 96(9 Suppl):S241.

RE-AIMS 7/22/2020 3:25:35 PM


34. Yousfi MM, Douglas DD, Savage WT, Balan V, Vargas H, Nelson L, Moss AA, Mulligan DC, Rakela J, Harrison ME. Screening colonoscopy prior to orthotopic liver transplantation (OLT)(Abstract 534). Am J Gastroenterol. 2001 Sep; 96;(9 suppl 1):S710.

35. Yousfi MM, Douglas DD, Mishark KJ, Harrison ME, Balan V, Vargas H, Rakela J, Blair JE. Varicella-Zoster hepatitis in an immunocompromised host: resolution of severe hepatitic necrosis with early administration of acyclovir. Am J Gastroenterol. 2001Sep; 96(9 Suppl1):S255.

36. Savage WT, Yousfi MM, Loutfi H, Mulligan DC, Harrison ME, Vargas HE, Balan V, Moss AA, Rakela J, Douglas DD. Cardiac events after orthotopic liver transplantation (OLT) (Abstract 473). Hepatology. 2001 Oct; 34(4 Pt. 2):290A.

37. Vargas HE, Rosati MJ, Douglas DD, Harrison ME, Mulligan DC, Moss AA, Rakela J, Balan V. Combination pegylated interferon alpha-2b and ribavirin in transplant patients with recurrent hepatitis C infection: A preliminary report (Abstract 939). Hepatology. 2001 Oct; 34(4 Pt. 2):407A.

38. Yousfi MM, Douglas DD, Harrison EM, Mulligan DC, Moss AA, Vargas HE, Rakela J, Hay EJ, Balan V. End-stage liver disease secondary to hepatitis C infection and alcohol is a risk factor for osteoporosis (Abstract 232). Hepatology. 2001 Oct; 34(4 pt. 2):231A.

39. Yousfi MM, Douglas DD, Harrison ME, Vargas HE, Mulligan DC, Moss AA, Malinchoc M, Wiesner RH, Rakela J, Balan V. Model for end stage liver disease (MELD): Dynamic changes in MELD score is important in predicting mortality for patients awaiting liver transplantation (LTx) (Abstract 323). Hepatology. 2001 Oct; 34(4 Pt. 2):254A.

40. Douglas DD, Brandhagen DJ, Rosen CB, Wiesner RH, Balan V, Hansen KL, Vargas HE, Harrison ME, Moss AA, Rakela J, Mulligan DC. Liver biopsy in the evaluation of living donors for liver transplantation is useful (Abstract 1135). Am J Transplant. 2002; 2(Suppl 3):424.

41. Mulligan DC, Post DJ, Rodriguez-Davalos MI, Jaroszewski DE, Moss AA, Douglas DD, Balan V, Vargas HE, Harrison ME, Rakela J, Gores G. Tacrolimus as a liver flush solution ameliorates ischemia/reperfusion injury following liver transplantation (LT) (Abstract 833). Am J Transplant. 2002; 2(Suppl 3):347.

42. Khatib MA, Vargas H, Rosati M, Douglas D, Harrison ME, Mulligan D, Moss A, Rakela J, Carey E, Balkan V. Treatment Of Recurrent HCV Post Orthotopic Liver Transplantation (OLT) With Pegylated Interferon Alpha 2b And Ribavirin: An Update. Gastroenterology. 2002; 123(1):80.

43. Rakela J, Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD, Harrison ME, Mulligan DC, Olden K, Adair D. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation (Abstract 247). Liver Transpl. 2002 Jun; 8(6):C-62.

44. Carey EJ, Douglas DD, Vargas HE, Balan V, Harrison ME, Rakela J. Prolongation of the QT-interval in patients with end stage liver disease--reversibility after liver transplantation? (Abstract 199). Liver Transpl. 2002 Jun; 8(6):C-50.

45. Carey EJ, Yancey LS, Blair JE, Douglas DD, Khatib MA, Harrison ME, Vargas HE, Balan V, Rakela J. Prolonged pre-transplant hospital stay does not increase VRE colonization in liver transplant recipients (Abstract 50). Liver Transpl. 2002 Jun; 8(6):C-13.

46. Khabit MA, Vargas H, Rosati M, Douglas D, Harrison ME, Mulligan D, Moss A, Rakela J, Carey E, Balan V. Treatment of recurrent Hepatitis C post orthotopic liver transplantation (OLT) with pegylated interferon alpha-2b and ribavirin: An update. Gastroenterology. 2002 Jul; 123(1 Suppl S):80-1.

47. Khatib MA, Balan V, Douglas D, Mulligan D, Anderson M, Vargas H, Carey E, Harrison ME. Role of ERCP in the evaluation and management of anastomotic strictures following liver transplantation a single center experience. Am J Gastroenterol. 2002 Sep; 97(9 Suppl S):S92.

48. Wilkinson J, Laskus T, Groninger H, Radkowski M, Adair D, Vargas HE, Buskell Z, Seeff L, Rakela J. Analysis of hepatitis C virus (HCV) quasispecies transmission and evolution in patients infected through blood transfusion: Differences associated with outcome. Hepatology. 2002 Oct; 36(4 Part 2):226A.

49. Laskus T, Radkowski M, Bednarska A, Wilkinson J, Adair D, Nowicki M, Vargas HE, Rakela J. Detection and analysis of hepatitis C virus sequences in cerebrospinal fluid. Hepatology. 2002 Oct; 36(4 Part 2):295A.

RE-AIMS 7/22/2020 3:25:35 PM


50. Carey EJ, Khatib MA, Douglas DD, Vargas HE, Balan V, Harrison ME, Rakela J, Moss A, Mulligan DC. Hepatopulmonary syndrome resolves after living donor liver transplantation (Abstract 2009). Hepatology. 2002 Oct; 36(4 Part 2):665A.

51. Arenas JI, Khatib MA, Groninger H, Wilkinson J, Williams J, Mulligan D, Douglas D, Netto G, Fasola CG, Laskus T, Klintmalm G, Rakela J, Vargas HE. Patterns of HCV quasispecies transmission and evolution after liver transplantation predict the severity of HCV recurrence. Hepatology. 2002 Oct; 36(4 Part 2):179A.

52. Carey EJ, Rosati M, Khatib MA, Harrison ME, Anderson M, Vargas HE, Rakela J, Balan V. Prevalence and clinical significance of elevated alpha-fetoprotein in non-cirrhotic patients with hepatitis C. Hepatology. 2002 Oct; 36(4 Part 2):564A.

53. Khatib MA, Arenas JI, Carey E, Moss A, Mulligan D, Ortiz J, Hansen K, Harrison ME, Douglas D, Balan V, Rakela J, Vargas HE. Treatment with combination of PEG IFN alpha-2b and ribavirin suppresses viral replication in liver transplantation recipients with recurrent HCV hepatitis (Abstract 64). Hepatology. 2002 Oct; 36(4 Part 2):182A.

54. Carey E, Rosati M, Khatib MA, Vargas H, Harrison ME, Anderson M, Douglas D, Rakela J, Balan V. Use of erythopoietin allows for optimal ribavirin dosing during therapy for hepatitis C virus with pegylated interferon and ribavirin (Abstract 1763). Hepatology. 2002 Oct; 36(4 Part 2):604A.

55. Carey E, Rosati M, Anderson M, Khatib MA, Vargas H, Harrison ME, Douglas D, Rakela J, Balan V. Use of G-CSF allows for optimal PEG-INF dosing during therapy for hepatitis C virus with pegylated interferon and ribavirin (Abstract 1764). Hepatology. 2002 Oct; 36(4 Part 2):604A.

56. Rodriguez-Luna H, Vargas H, Byrne T, Moss A, Mulligan DC, Balan V, Rakela J, Douglas DD. Hepatitis C virus recurrence in living donor liver transplantation vs. cadaveric liver transplantation (Abstract 34). American Journal of Transplantation. 2003; 3(S5):160.

57. Sharma P, Balan V, Rodriguez-Luna H, Jose H, Douglas DD, Vargas H, Rakela J, Wiesner RH. Outcome of liver transplantation (LT) for familial amyloidotic polyneuropathy type 1 (FAP) (Abstract 887). Am J Transplant. 2003; 3(Suppl 5):379.

58. Douglas DD, Gauthier S, Anderson K, Balan V, Vargas H, Byrne T, Harrison W, Rakela J, Moss A, Mulligan DC. Positive economic impact of the MELD allocation system on decreasing need for pretransplantation hospitalization (Abstract 360). Am J Transplant. 2003; 3(Suppl 5):244.

59. Carey EJ, Douglas DD, Moss AA, Balan V, Vargas HE, Rakela J, Harrison ME, Byrne TJ, Mulligan DC. Reversal of hepatopulmonary syndrome after cadaveric and living donor liver transplantation: a single center experience (Abstract 351). Am J Transplant. 2003; 3(Suppl 5):241.

60. Douglas DD, Blair J, Sharma P, Balan V, Vargas H, Byrne T, Rakela J, Harrison W, Moss A, Mulligan DC. The effect of anti-fungal prophylaxis on outcomes after adult living donor liver transplant (LDLT) (Abstract 1441). Am J Transplant. 2003; 3(Suppl 5):522.

61. Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Moss A, Mulligan D, Bahn V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combinations of PEG-IFN alpha2B and ribavirin: an open label series (Abstract 23). Liver Transpl. 2003 Jun; 9(6):C-6.

62. Arenas JI, Laskus T, Wilkinson J, Gallegos JF, Fasola CG, Adair D, Radowski M, Kibler KV, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Rejection treatment modifies HCV quasispecies evolution after liver transplantation. Hepatology. 2003 Oct; 38(4 Suppl. 1):532A.

63. Rodriguez-Luna H, Balan V, Sharma P, Byrnes T, Douglas DD, Rakela J, Vargas HE. Hepatocellular carcinoma with and without Hepatitis C Virus Infection, a controversial indication for liver transplantation: Maybe not!. Hepatology. 2003 Nov; 38(5):1325.

64. Harrison ME, Nguyen C, Vargas HE, Balan V, Douglas DD, Moss AA, Reddy KS, Mulligan DC, Rakela J. Diagnosis and endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplant: update of a single center experience (Abstract 220). Am J Gastroenterol. 2004 Oct; 99(10 Suppl):S72-3.

65. Sachdev MS, Petre SA, Vargas HE. Post transplant inflammatory bowel disease (Abstract 674). Am J Gastroenterol. 2004 Oct; 99(10 Suppl):S219.

RE-AIMS 7/22/2020 3:25:35 PM


66. Gallegos-Orozco JF, Arenas JI, Kibler KV, Wilkinson JK, Adair D, Radkowski M, Vargas HE, Laskus T, Rakela J. Translation efficiency of hepatitis C virus 5'-untranslated region variants developing in transfusion acquired infection and in post-transplant recurrent hepatitis (Abstract 1204). Hepatology. 2004 Oct; 40(4 Suppl 1):688A-689A.

67. Byrne TJ, Douglas DD, Vargas HE, Balan VC, Harrison ME, Moss A, Reddy KS, Rakela J, Mulligan DC. Does model for end-stage liver disease (MELD) score correlate with quality of life? (Abstract 250). Am J Transplant. 2005; 5(Suppl 11):219.

68. Orrego M, Vargas H, De Petris G, Douglas D, Byrne T, Balan V, Guo L, Reddy K, Harrison E, Moss A, Mulligan D, Rakela J. Donor age influences survival of liver transplant recipients (Abstract 698). Am J Transplant. 2005; 5(Suppl 11):334.

69. Gallegos-Orozco JF, Zhang J, Laskus T, Vargas HE, Mulligan DC, Reddy KS, Moss A, Rakela J, Byrne TJ. Hepatitis C virus quasispecies in liver transplant recipients with and without hepatocellular carcinoma (Abstract 98). Am J Transplant. 2005; 5(Suppl 11):181.

70. Rodriguez-Luna H, Guo L, Orrego M, DePetri G, Byrne T, Mulligan D, Douglas DD, Rakela J, Vargas HE. Histological changes among patients with sustained viral repsonse after successful treatment for recurrent heparitis C virus (Abstract 1451). Am J Transplant. 2005; 5(Suppl 11):525.

71. Byrne TJ, Douglas DD, Lopez J, Hansen KL, Balan V, Harrison W, Rakela J, Vargas H, Moss AA, Reddy KS, Mulligan DC. Improvement in quality of life after liver transplantation: living donor vs deceased donor (Abstract 205). Am J Transplant. 2005; 5(Suppl 11):208.

72. Orrego M, Vargas H, Douglas D, Byrne T, Balan V, Guo L, Moss A, Rakela J, Reddy KS, Liu P, Mulligan DV. Long-term follow-up of biliary anatomy in adult right lobe liver donors (Abstract 734). Am J Transplant. 2005; 5(Suppl 11):343.

73. Guo L, Orrego M, Rodriguez-Luna H, Balan V, Byrne T, Moss A, Williams JW, Reddy KS, Harrison ME, De Petris G, Rakela J, Douglas DD, Mulligan D, Vargas HE. No difference in histological recurrent hepatitis C between living donor and deceased donor liver transplant recipients (Abstract 476). Am J Transplant. 2005; 5(Suppl 11):277-8.

74. Mulligan DC, Moss A, Reddy K, Esparra B, Byrne T, Vargas H, Balan V, Douglas D, Rakela J, Collins J. To preserve or not to preserve the middle hepatic vein; that is the question, or is it? Can we better define the anatomy to safely divide the liver for successful living donor liver transplantation? (Abstract 1554). Am J Transplant. 2005; 5(Suppl 11):551.

75. Douglas DD, Moss AA, Reddy KS, Durocher D, Rakela J, Vargas HE, Balan V, Byrne TJ, Harrison ME, Mulligan DC. Hospital cost of right hepatectomy: adult-to-adult living donor vs. benign and malignant indications (Abstract 65). J Gastrointest Surg. 2005 Apr; 9(4):546.

76. Wells CD, Balan V, Smilack JD, Orrego M, Vargas HE, Heigh RI, Carey EJ. Pyogenic liver abscess following colonoscopy in a patient with ulcerative colitis (Abstract 688). Am J Gastroenterol. 2005 Sep; 100(9 Suppl):S259.

77. Douglas DD, Russell LE, Boyer JA, Byrne TJ, Balan V, Vargas HE, Rakela J, Harrison ME, Chopra K, Reddy KS, Moss AA, Mulligan DC. Changes in SF-36 quality of life (QOL) variables after right hepatectomy for adult living donor liver transplantation (ALDLT) (Abstract 650). Hepatology. 2005 Oct; 42(4 Suppl 1):452A-453A.

78. Gallegos JF, Rakela J, Rosati MJ, Vargas H, Balan V. Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C (CHC) with pegylated interferon and ribavirin (Abstract 940). Hepatology. 2005 Oct; 42(4 Suppl 1):565A-566A.

79. Mai AM, Sirven JI, Drazkowski JF, Noe KH, Vargas H. Seizures in patients with chronic hepatitis C virus infection (Abstract P03.125). Neurology. 2006 Mar; 66(5 Suppl 2):A163.

80. Cheruvattath R, Douglas DD, Russell LE, Byrne TJ, Balan V, Vargas HE, Rakela J, Chopra K, Reddy KS, Moss AA, Mulligan DC. Changes in SF-36 quality of life (QOL) scales after right hepatectomy for adult living donor liver transplantation (ALDLT) (Abstract 303). Liver Transpl. 2006 May; 12(5):C-76.

RE-AIMS 7/22/2020 3:25:35 PM


81. Umphrey LG, Lee KS, Reuss CS, Hentz JG, Vargas HE, Appleton CP, Hurst RT. Dobutamine echocardiographic findings and adverse cardiac events in orthotopic liver transplant recipients (Abstract LB-53). Liver Transpl. 2006 May; 12(5):C-128.

82. Cheruvattath R, Douglas DD, Russell LE, Byrne TJ, Balan V, Vargas HE, Rakela J, Chopra K, Carey EJ, Harrison ME, Reddy KS, Moss AA, Mulligan DC. Changes in SF-36 quality of liver scales after right hepatectomy for adult living donor liver transplantation (ALDLT). Am J Transplant. 2006 Aug; 6(s2):466.

83. Cheruvattath R, Gautam M, Chopra K, Carey E, Sharma VK, Kears J, Corrado C, Webster S, Hughes L, Rukela J, Vargas HE. Applicability of capsule endoscopy in screening for portal hypertension (Abstract 352). Am J Gastroenterol. 2006 Sep; 101(9):S161.

84. Pottage JC, Lawitz E, Mazur D, Wyles D, Vargas H, Ghalib R, Gughotti R, Donohue M, Robison H. Short-term antiviral activity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype I infected individuals. J Hepatol. 2007; 46(Suppl 1):S294-5.

85. Carey EJ, Douglas DD, Vargas HE, Byrne TJ, Balan V, Rakela JL. Inpatient admissions for drug-induced liver injury: Results from a single center. Gastroenterology. 2007 Apr; 132(4 Suppl 2):A773-4.

86. Singh V, Carey EJ, Rudraraju M, Rosati MJ, Grumeretz CA, Balan V, Vargas HE. Role of HMG-CoA reductase therapy in hepatitis c (HCV) treatment outcomes. Gastroenterology. 2007 Apr; 132(4 Suppl 2):A789-90.

87. Mekeel KL, Moss AA, Douglas DD, Harrison ME, Vargas HE, Byrne TJ, Balan V, Carey EJ, Reddy KS, Mulligan DC. Impact of gender mismatch in living donor liver transplantation (Abstract 264). Am J Transplant. 2007 May; 7(Suppl 2):215.

88. Carey EJ, Douglas DD, Vargas HE, Byrne TJ, Rakela J, Mekeel KL, Reddy KS, Moss AA, Mulligan DC. Reversal of hepatopulmonary syndrome after cadaveric and living donor liver transplantation: A single center experience (Abstract 1549). Am J Transplant. 2007 May; 7(Suppl 2):545.

89. Carey EJ, Douglas DD, Vargas HE, Byrne TJ, Balan V, Rakela J, Mulligan DC. The effect of liver transplantation on autonomic dysfunction in patients with end-stage liver disease. Am J Transplant. 2007 May; 7(Suppl 2):545-6.

90. Gautam M, Rosati MJ, Werner KT, Vargas HE, Balan V. Does chronic kidney disease progress during treatment of chronic hepatitis C infection (poster presentation). Digestive Disease Week Washington DC. May 19-24, 2007.

91. De Franchis R, Eisen GM, Eliakim AR, Sahota A, Fernandez-Urien I, Herrerias JM, Goldstein JL, Vargas HE, Fisher L. Esophageal capsule endoscopy (PillCam ESO) is comparable to traditional endoscopy for detection of esophageal varices - an international multi-center trial. Digestive Disease Week Washington DC. May 19-24, 2007.

92. Carey EJ, Douglas DD, Vargas HE, Byrne TJ, Balan V, Rakela JL. Inpatient admissions for drug-induced liver injury: results from a single center (poster presentation). Digestive Disease Week Washington DC. May 19-24, 2007.

93. Carey EJ, Douglas DD, Vargas HE, Byrne TJ, Rakela JL, Balan V, Mulligan DC. The effect of liver transplantation on autonomic dysfunction in patients with end-stage liver disease (poster presentation). Digestive Disease Week Washington DC. May 19-24, 2007.

94. Reddy R, Rodriguez-Torres M, Gane E, Robson R, Lalezari J, Everson GT, Dejesus E, McHutchison JG, Vargas HE, Beard A, Rodriguez CA, Hill GZ, Symonds W, Berrey M. Antiviral activity, pharmacokinetics, safety and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy. Hepatology. 2007 Oct; 46(4 Suppl S):862A-3A.

95. Moss AA, Mekeel KL, Reddy KS, Harrison ME, Douglas DD, Vargas H, Carey E, Byrne T, Mulligan DC. A change in biliary anastomotic technique leads to a significant impact on complications following adult living donor liver transplantation (LDLT) (Abstract 1638). Am J Transplant. 2008 May; 8(Suppl 2):613.

96. Gallegos-Orozco JF, Vargas HE, Netto G, Davis GL, Eckhoff DE, Klintmalm GB. Hepatitis C E2 region diversity after liver transplantation: A report from the hepatitis C III trial. Am J Transplant. 2008 May; 8(Suppl 2):196.

RE-AIMS 7/22/2020 3:25:35 PM


97. Wemer K, Mulligan D, Vargas H, Carey E, Douglas D, Crowell M, Rakela J, Byrne T. Influence of age and locoregional therapy on the outcome of liver transplantation for hepatocellular carcinoma. Am J Transplant. 2008 May; 8(Suppl 2):382.

98. Jatoi MA, Douglas DD, Byrne TJ, Carey EJ, Harrison ME, Mekeel KL, Moss AA, Rakela J, Reddy KS, Vargas HE, Mulligan DC. Positive economic impact of MELD exception cases on hospital utilization (Abstract 805). Am J Transplant. 2008 May; 8(Suppl 2):394.

99. Jatoi MA, Douglas DD, Byrne TJ, Carey EJ, Harrison ME, Mekeel KL, Moss AA, Rakela J, Reddy KS, Vargas HE, Mulligan DC. Economic impact of recipient Meld score, but not donor risk index on hospital utilization. Liver Transpl. 2008 Jul; 14(7 Suppl 1):S218-9.

100.

Mekeel KL, Harrison ME, Das A, Douglas DD, Vargas HE, Carey EJ, Aqel B, Byrne TJ, Reddy KS, Moss A, Mulligan DC. Endoscopic and percutaneous treatment of biliary anastamotic strictures after living donor liver transplantation. Hepatology. 2008 Oct; 48(4 Suppl S):632.

101.

Carey EJ, Douglas DD, Vargas HE, Rakela JL, Byrne TJ, Aqel B, Chakkera H. Incidence and risk factors for new onset diabetes mellitus after liver transplantation. Hepatology. 2008 Oct; 48(4 Suppl S):574.

102.

Mekeel KL, Moss A, Reddy KS, Douglas DD, Vargas HE, Carey EJ, Byrne T, Aqel B, Harrison ME, Mulligan DC. Outcomes of living donor liver transplantation for primary sclerosing cholangitis in patients with Meld scores less than 15. Hepatology. 2008 Oct; 48(4 Suppl S):642.

103.

Jatoi M, Walker F, Jeevanantham V, Silva A, Carey EJ, Rakela JL, Byrne TJ, Douglas DD, Richard E, Aqel B, Vargas HE. Role of magnetic resonance elastography (Mre) in assessing hepatic fibrosis. Hepatology. 2008 Oct; 48(4 Suppl S):1546.

104.

Rosati MJ, Aqel B, Balan V, Byrne TJ, Carey EJ, Douglas DD, Harrison ME, Heilman RL, Mazur MJ, Mekeel KL, Moss A, Mulligan DC, Reddy KS, Rakela J, Vargas HE. Treatment of hepatitis C in renal failure patients: a single center experience. Hepatology. 2008 Oct; 48(4 Suppl S):1319.

105.

Gallegos-Orozco JF, Yosephy A, Noble B, De Petris G, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Reddy KS, Rakela J, Vargas HE. Impact of liver fibrosis in patients with post-liver transplant hepatitis C recurrence. Am J Transpl. 2009; 9(Suppl 2):377.

106.

Yosephy A, Gallegos-Orozco JF, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Moss A, Mulligan D, Rakela J, Vargas HE. Living-donor vs. deceased-donor liver transplantation in patients with hepatitis C: a single center experience. Am J Transplant. 2009; 9(Suppl 2):699.

107.

Yosephy A, Gallegos-Orozco JF, Byrne TJ, Noble B, Aqel B, Carey E, Douglas DD, Mulligan D, Rakela J, Vargas HE. Natural history of hepatitis c after liver transplantation: a single center experience. J Hepatol. 2009; 50:498.

108.

Yosephy A, Byrne TJ, Carey EE, Hansen K, Douglas DD, Mulligan D, Rakela JJ, Vargas HE, Aqel BA. Natural history of fibrosing cholestatic hepatitis C (FCH) after liver transplantation: a single center experience. Liver Transpl. 2009 Jul; 15(Suppl 1):S93.

109.

Carey EJ, Aqel B, Byrne TJ, Vargas HE, Rakela J, Douglas DD, Chakkera H. Incidence and risk factors for new onset diabetes mellitus after liver transplantation. Hepatology. 2009 Oct; 50(Suppl S):563.

110.

Sozama M, Yosephy A, Mekeel KL, De Petris G, Naidu SG, Silva AC, Appleton CP, Aqel B, Byrne TJ, Carey EJ, Douglas DD, Rakela J, Vargas HE. Post-liver transplantation ascites (PLTA): evolution, evaluation and management, a ten-year single center experience. Hepatology. 2009 Oct; 50(Suppl S):591.

111.

Lalezari J, Asmuth D, Casiro A, Vargas HE, Patrick GD, Liu W, Pietropaolo K, Zhou XJ, Sullivan-Bolyai J, Mayers DL. Antiviral activity, safety and pharmacokinetics of idx184, a liver-targeted nucleotide HCV polymerase inhibitor, in patients with chronic hepatitis C. Hepatology. 2009 Dec; 50(6):LB18.

112.

Gordon FD, Brown RS, Kwo P, Ghalib RJ, Crippin J, Vargas H, Brown K, Schiano T, Yu X, Chaudhri E, Pedicone L. Peginterferon alfa-2B and ribavirin for hepatitis c recurrence post orthotopic liver transplantation (OLT): final results from the protect study. J Hepatol. 2010; 52(Suppl 1):S10-1.

113.

Mulligan DC, Moss AA, Mekeel KL, Rakela J, Byrne TJ, Carey EJ, Vargas HE, Aqel BA, Douglas DD, Reddy KS. Extended recipient middle hepatic vein utilization for optimal venous drainage in living donor liver transplantation. Am J Transplant. 2010 Apr; 10(Sp Iss SI Suppl 4):271.

RE-AIMS 7/22/2020 3:25:35 PM


114.

Hsieh TH, Yosephy A, Aqel B, Byrne T, Carey E, Douglas D, Harrison E, Rakela J, Vargas H. Hepatic abscess in liver transplant recipients: trend in era of living donor liver transplantation, a single center 10-year experience. Am J Transplant. 2010 Apr; 10(Sp Iss SI Suppl 4):427.

115.

Sharma P, Byrne T, Welch K, Amir Y, Vargas H, Marrero J, Merion R. Hepatocellular carcinoma-recurrence risk index may predict post-transplant hepatocellular carcinoma recurrence better than milan criteria. Am J Transplant. 2010 Apr; 10(Sp Iss SI Suppl 4):451.

116.

Moss AA, Douglas DD, Reddy KS, Mekeel KL, Carey EJ, Aqel BA, Byrne TJ, Vargas HE, Rakela J, Mulligan DC. Liver transplantation in the obese class II and III recipient(Abstract #763). Am J Transplant. 2010 Apr; 10(Sp Iss SI Suppl 4):263.

117.

Hsieh TH, Byrne T, Carey E, Aqel B, Hsieh HL, Vargas H, Douglas D, Rakela J, Mulligan D. Living- and deceased-donor liver transplantation for hepatocellular carcinoma at a single center: comparison of clinical parameters and outcomes. Am J Transplant. 2010 Apr; 10(Sp Iss SI Suppl 4):271-2.

118.

Carey EJ, Steidley E, Aqel BA, Douglas DD, Vargas HE, Byrne TJ, Mekeel KL, Moss AA, Reddy KS, Mulligan DC, Rakela J. Six minute walk test predicts pre-and post-transplant mortality in patients listed for liver transplantation. Liver Transpl. 2010 Jun; 16(Suppl 1):S152.

119.

Gallegos-Orozco JF, Aqel B, Carey EJ, Byrne TJ, Hansen KL, Ellis TL, Douglas DD, Rakela J, Vargas HE. Long-term outcome of HCV treatment with peginterferon for recurrent disease after liver transplantation. Hepatology. 2010 Oct; 52(Suppl S):771A.

120.

Hsieh TH, Byrne T, Carey E, Douglas D, Harrison ME, Rakela J, Vargas H, Aqel B. Role of antibiotics use in patients with cirrhosis and acute variceal bleeding: single center experience. Am J Gastroenterol. 2010 Oct; 105(Suppl 1):317.

121.

Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Mur RE, Everson G, Fallon M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Ramos E, Lopez-Talavera JC, Muir A. Pegylated interferon-lambda (PEGIFN-lambda) shows superior viral response with improved safety and tolerability versus PEGIFN alpha-2a in HCV patients (g1/2/3/4): emerge phase iib through week 12. J Hepatol. 2011 Mar; 54(1):S538-9.

122.

Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Meadows-Shropshire S, Agarwal M, Garcia-Valdecasas JC. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II study. Am J Transplant. 2011 Apr; 11(Suppl 2):137.

123.

Garcia-Valdecasas JC, Feng S, Lake JR, Vargas HE, Wekerle T, Meadows-Shropshire S, Agarwal M, Klintmalm GB. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase ii study. Liver Transpl. 2011 Jun; 17(Suppl 1):S79.

124.

Hsieh TH, Harrison ME, Crowell MD, Mekeel KL, Aqel B, Carey EJ, Byrne TJ, Vargas HE, Douglas DD, Rakela J, Reddy KS, Moss A, Mulligan DC. Combination of running and interrupted sutures significantly decreases biliary strictures after living donor liver transplant. Hepatology. 2011 Oct; 54(1):680A-1A.

125.

Aqel B, Werner KT, Sando S, Carey EJ, Vargas HE, Douglas DD. Portal vein thrombosis (PVT) in patients with liver cirrhosis: outcome of screening and anticoagulation. Hepatology. 2011 Oct; 54(1):1267A.

126.

Byrne TJ, Ashman J, Aqel B, Carey EJ, Douglas DD, Harrison ME, Rakela J, Vargas HE. Preliminary experience with stereotactic body radiation therapy (SBRT) for unresectable hepatocellular carcinoma. Hepatology. 2011 Oct; 54(1):1392A-3A.

127.

Batheja MJ, Chang YHH, Harrison ME, Vargas HE, Douglas DD, Carey EJ, Aqel B. Rate of early GI rebleeding after esophageal variceal ligation. Hepatology. 2011 Oct; 54(1):942A-3A.

128.

Rodriguez-Torres M, Hillson JL, Bacon BR, Box TD, Hassanein T, Greenbloom S, Lawitz E, Vargas HE, Vierling JM, Horga M, Ramos E, Fontana D, Freeman JA, Gray TE, Bittner R, Xu D, Ishak L, Lopez-Talavera JC. Safety and efficacy of pegylated interferon lambda (peg-lambda) compared to pegylated interferon alpha-2a (peg-alfa) in hcv-infected patients (g1/2/3) with compensated cirrhosis: emerge phase iib efficacy and safety results through week 12. Hepatology. 2011 Oct; 54(1):994A-5A.

RE-AIMS 7/22/2020 3:25:35 PM


129.

Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Mur RE, Everson G, Fallon M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee SS, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Gray T, Horga A, Hillson J, Lopez-Talavera JC, Muir A. Peginterferon lambda-1a (lambda) compared to peginterferon alfa-2a (alfa) in treatment-naive patients with hcv genotypes (g) 2 or 3: first svr24 results from emerge phase iib. J Hepatol. 2012 Apr; 56:S5-6.

130.

Gallegos-Orozco JF, Silva AM, Chang YH, Batheja MJ, Hansen KN, Lam-Himlin D, De Petris G, Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Mulligan DC, Silva A, Vargas HE. Magnetic resonance elastography (MRE) can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. Liver Transpl. 2012 May; 18:S111.

131.

Yadav A, Chang YH, Aqel B, Byrne T, Chakkera H, Douglas D, Mulligan D, Rakela J, Vargas H, Carey E. New onset diabetes mellitus in living donor versus deceased donor liver transplant recipients: analysis of the unos/optn database. Am J Transplant. 2012 May; 12:108-9.

132.

Lawitz E, Box TD, Pruitt R, Rodriguez-Torres M, Nguyen TT, Lalezari JP, Vargas HE, Goff JS, Hinestrosa F, Luketic VA, Mehra P, Dubuc-Patric G, Donovan EF, Chen J, Pietropaolo K, Zhou XJ, Sullivan-Bolyai J, Mayers DL. High rates of rapid virologic response (rvr) and complete early virologic response (cevr) with idx184, pegylated interferon and ribavirin in genotype 1 hcv-infected subjects: interim results. Hepatology. 2012 Oct; 56:1006A-7A.

133.

Gallegos-Orozco JF, Chervenak AE, Carey EJ, Aqel B, Byrne TJ, Hartel LA, Rakela J, Vargas HE. Liver transplant center focused experience with peginterferon alfa-2a, ribavirin and telaprevir therapy in patients with genotype 1 hepatitis c cirrhosis. Hepatology. 2012 Oct; 56:218A-9A.

134.

Aqel B, Koning L, Charlton M, Carey EJ, Byrne TJ, Rakela J, Vargas HE. Multicenter preliminary experience utilizing boceprevir with pegylated interferon and ribavirin for treatment of recurrent hepatitis c genotype 1 after liver transplantation. Hepatology. 2012 Oct; 56:530A.

135.

Terrault N, Hassanein T, Joshi S, Lake JR, Sher LS, Vargas HE, McIntosh JW, Tang SD, Jenkins T. Once-daily oral avatrombopag (e5501) prior to elective surgical or diagnostic procedures in patients with chronic liver disease and thrombocytopenia: results from a phase 2, randomized, double-blind, placebo-controlled study (study 202). Hepatology. 2012 Oct; 56:253A-4A.

136.

Chervenak AE, Aqel B, Byrne TJ, Carey EJ, Rakela J, Harte LA, Gallegos-Orozco JF, Sapola AM, Vargas HE. Treatment of HCV in the DAA era: the impact of a multidisciplinary team. Hepatology. 2012 Oct; 56:228A.

137.

Corey R, Whitaker M, Crowell MD, Aqel B, Balan V, Byrne TJ, Carey EJ, Chang YHH, Douglas DD, Harrison ME, Vargas HE, Rakela J. Vitamin D deficiency, parathyroid hormone (PTH) levels, and bone disease among patients with end stage liver disease (ESLD) awaiting liver transplantation (LT). Hepatology. 2012 Oct; 56:941A.

138.

Corey R, Whitaker M, Crowell MD, Aqel B, Balan V, Byrne TJ, Carey EJ, Chang YHH, DiBaise J, Douglas DD, Harrison ME, Vargas HE, Rakela J. Vitamin D, A, and E deficiencies among patients with end stage liver disease (ESLD) awaiting liver transplantation (LT). Hepatology. 2012 Oct; 56:945A-6A.

139.

Aqel B, Carey E, Douglas D, Byrne T, Rakela J, Susan W, Vargas H. Preliminary experience utilizing boceprevir with pegylated interferon and ribavirin for treatment of recurrent hepatitis C genotype 1 after liver transplantation. Am J Transplant. 2013 Apr; 13:144.

140.

Vargas H, Dai Y, Brown K, Russo M, Yoshida E, Fontana R, Levitsky J, Rubin R, Garg V, Brown R. Twice daily telaprevir in combination with peginterferon alfa-2a/ribavirin in hcv genotype 1 liver transplant recipients: interim pharmacokinetics of the refresh study. Am J Transplant. 2013 Apr; 13:347.

141.

Brown R, Russo M, Levitsky J, Brown K, Fontana R, Vargas H, Yoshida E, Bsharat M, Rubin R. Twice daily telaprevir in combination with peginterferon alfa-2a/ribavirin in hcv genotype 1 liver transplant recipients: interim safety/efficacy of the refresh study. Am J Transplant. 2013 Apr; 13:145.

RE-AIMS 7/22/2020 3:25:35 PM


142.

Yadav A, Chang Y, Carpenter S, Silva A, Aqel B, Byrne T, Douglas D, Vargas H, Carey E. Six minute walk distance enhances pre-operative evaluation in candidates for liver transplantation. Liver Transpl. 2013 Jun; 19:S176.

143.

Yadav A, Chang Y, Carpenter S, Silva A, Aqel B, Byrne T, Douglas D, Vargas H, Carey E. Vitamin d deficiency and six minute walk distance in candidates listed for liver transplantation. Liver Transpl. 2013 Jun; 19:S297.

144.

Boyle SS, Aqel B, Carey EJ, Douglas DD, Rakela J, Vargas HE, Byrne TJ. Morbidity and mortality following radiofrequency- and microwave ablation in patients with hepatocellular carcinoma. Hepatology. 2013 Oct; 58:1274A.

145.

Yadav A, Chang YHH, Silva AC, Aqel B, Byrne TJ, Douglas DD, Vargas HE, Carey EJ. Six minute walk distance predicts waitlist mortality more accurately than sarcopenia in liver transplant candidates. Hepatology. 2013 Oct; 58:1016A.

146.

Fontana RJ, Qiu RL, Russo MW, Yoshida EM, Brown KA, Levitsky J, Vargas HE, Rubin RA, Garg V, Brown RS. Twice-daily telaprevir in combination with peginterferon alfa-2a/ribavirin in genotype 1 hcv liver transplant recipients: interim week 16 calcineurin inhibitor, telaprevir, and ribavirin pharmacokinetics from the prospective multicenter refresh study. Hepatology. 2013 Oct; 58:1043A.

147.

Brown KA, Fontana RJ, Russo MW, Levitsky J, Yoshida EM, Vargas HE, Bsharat M, Rubin RA, Brown RS. Twice-daily telaprevir in combination with peginterferon alfa-2a/ribavirin in genotype 1 hcv liver transplant recipients: interim week 16 safety and efficacy results of the prospective, multicenter refresh study. Hepatology. 2013 Oct; 58:209A.

148.

Yadav A, Chang YHH, Silva AC, Aqel B, Byrne TJ, Douglas DD, Vargas HE, Carey EJ. Vitamin d deficiency is associated with decreased functional capacity in patients with cirrhosis. Hepatology. 2013 Oct; 58:896A-7A.

149.

Mantry PS, Kwo PY, Coakley E, Te HS, Vargas HE, Brown RS, Gordon FD, Levitsky J, Terrault N, Burton JR, Xie WG, Setze C, Badri P, Vilchez RA, Forns X. High sustained virologic response rates in liver transplant recipients with recurrent hcv genotype 1 infection receiving abt-450/r/ombitasvir plus dasabuvir plus ribavirin. Hepatology. 2014; 60:298A-9A.

150.

Byrne TJ, Carey EJ, Aqel B, Douglas DD, Timm V, Dosmann M, Whitten P, White MR, Rakela J, Vargas HE. Impact of electronic reminder to improve hepatitis C screening in age-appropriate patients: results of a pilot quality improvement intervention. Hepatology. 2014; 60:911A-2A.

151.

Pungpapong S, Werner KT, Aqel B, Leise MD, Murphy JL, Henry TM, Ryland K, Chervenak AE, Watt KD, Vargas HE, Keaveny A. Multicenter experience using sofosbuvir and simeprevir with/without ribavirin to treat hcv genotype 1 after liver transplantation. Hepatology. 2014; 60:201A.

152.

Aqel B, Langlais P, Vargas HE, Carey EJ, Leonard M, Mandarino LJ. Prospective assessment of the abundance of drug metabolizing enzymes in the p450 pathway in patients with non alcoholic fatty liver disease (nafld). Hepatology. 2014; 60:759A.

153.

Sanyal AJ, Boyer TD, Frederick RT, Regenstein F, Rossaro L, Araya V, Vargas HE, Reddy KR, Jamil K, Pappas SC. Reversal of hepatorenal syndrome type 1 (hrs-1) with terlipressin plus albumin versus placebo plus albumin - not all responses are created equal - an analysis of the reverse and ot-0401 trials. Hepatology. 2014; 60:322A.

154.

Sulkowski MS, Vargas HE, Di Bisceglie AM, Kuo A, Reddy KR, Lim JK, Morelli G, Feld JJ, Brown RS, Frazier LM, Fried MW, Nelson DR, Jacobson IM. Safety and efficacy of sofosbuvir (sof) in combination with simeprevir (sim) plus ribavirin (rbv) in patients with genotype 1: interim results of a prospective, observational study. Hepatology. 2014; 60:660A-1A.

155.

Fortune BE, Garcia-Tsao G, Ciarleglio M, Deng YH, Fallon MB, Sigal S, Chalasani NP, Lim JK, Reuben A, Vargas HE, Abrams G, Lewis MB, Hassanein T, Trotter JF, Sanyal AJ, Beavers KL, Ganger D, Thuluvath PJ, Grace ND, Groszmann RJ. The Child-Turcotte-Pugh (CTP) score is best at predicting 6-week mortality in patients with acute variceal hemorrhage (avh): analysis of a US multi-center prospective study. Hepatology. 2014; 60:1202A.

RE-AIMS 7/22/2020 3:25:35 PM


156.

Aqel B, Pungpapong S, Werner KT, Chervenak AE, Rakela J, Watt KD, Leise MD, Murphy JL, Henry TM, Ryland K, Keaveny A, Vargas HE. The use of simeprevir and sofosbuvir to treat hcv g1 in the liver transplant setting: the experience in 3 US centers. Hepatology. 2014; 60:206A.

157.

Werner KT, Chervenak AE, Hartel LA, Aqel B, Balan V, Byrne TJ, Carey EJ, Vargas HE, Rakela J. Treatment of hcv in the sof era: experience in difficult to treat patients in a US liver transplant center. Hepatology. 2014; 60:704A.

158.

Unzueta A, Moreira RK, DePetris G, Smith ML, Chang YHH, Cheng MR, Eyshou A, Gallegos-Orozco JF, Aqel B, Vargas HE. Validation of the hepatitis aggressiveness score in a liver transplant population with recurrent hepatitis C. Hepatology. 2014; 60:535A-6A.

159.

Mantry P, Kwo P, Coakley E, Te H, Vargas H, Brown R Jr, Gordon F, Levitsky J, Terrault N, Burton J Jr, Xie W, Setze C, Badri P, Vilchez R, Forns X. M12-999:abt-450/r/abt-267+abt-333+ribavirin in liver transplant recipients with recurrent hcv genotype 1 infection. Am J Transplant. 2014 Jun; 14:3-4.

160.

Reynolds J, Chang Y, Chakkera H, Aqel B, Byrne T, Douglas D, Moss A, Vargas H, Carey E. Prospective analysis of predictors of new onset diabetes after liver transplantation. Am J Transplant. 2014 Jun; 14:746.

161.

Mantry P, Kwo P, Coakley E, Te H, Vargas H, Brown R Jr, Gordon F, Levitsky J, Terrault N, Burton J Jr, Xie W, Setze C, Badri P, Vilchez R, Forns X. M12-999:abt-450/r/abt-267+abt-333+ribavirin in liver transplant recipients with recurrent hcv genotype 1 infection. Transplantation. 2014 Jul 15; 98:3-4.

162.

Reynolds J, Chang Y, Chakkera H, Aqel B, Byrne T, Douglas D, Moss A, Vargas H, Carey E. Prospective analysis of predictors of new onset diabetes after liver transplantation. Transplantation. 2014 Jul 15; 98:746.

163.

Brown RS, Reddy KR, O'Leary JG, Kuo A, Morelli G, Stravitz RT, Durand CM, Di Bisceglie AM, Vargas HE, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. AASLD, Boston, MA. 2014 Nov.

164.

O'Leary J, Brown R, Reddy K, Kuo A, Morelli G, Stravitz R, Everson G, Durand C, Vargas H, Kwo P, Frenette C, Peter J, Vainorius M, Akushevich L, Nelson D, Fried M, Terrault N. Safety and efficacy of all oral daa therapy for genotype 1 hcv post-liver transplant: interval results from the hcv-target multicenter prospective observational study American Journal Of Transplantation. 2015 May; 15:

165.

Horsley-Silva JL, Menias CO, Smith M, Carballido E, Lindor K, Vargas H. Docetaxel induced sclerosing cholangitis. Am J Gastroenterol. 2015 Oct; 110:S365-6.

166.

Jacobson IM, Welzel TM, Vargas HE, Pedrosa MC, Terrault N, Dieterich D, Gordon FD, Kowdley KV, Neff G, Liu R, Lopez-Talavera JC, Zeuzem S. Efficacy, change in meld score, and safety by baseline meld score in patients with compensated cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in the phase 3 turquoise-ii trial Hepatology. 2015 Oct; 62:754A.

167.

Yang JD, Aqel BA, Watt KD, Vargas HE, Keaveny AP, Pungpapong S, Gores GJ, Roberts LR, Leise MD. Hepatitis c and hcc outcomes among patients listed for liver transplant with hcv-hcc who received direct acting antiviral therapy Hepatology. 2015 Oct; 62: 763A-4A.

168.

Wyles DL, Sulkowski MS, Wang S, Bennett M, Vargas HE, Overcash JS, Maliakkal B, Siddique A, Bhandari BR, Poordad F, Lovell SS, Lin CW, Ng T, Mensa FJ, Kort J. High svr4 rates achieved with the next generation ns3/4a protease inhibitor abt-493 and ns5a inhibitor abt-530 in non-cirrhotic treatment-naive and treatment-experienced patients with hcv genotype 2 infection (surveyor-2) Hepatology. 2015 Oct; 62:339A-40A.

169.

Kwo PY, Bennett M, Wang S, Vargas HE, Wyles DL, Overcash JS, Ruane PJ, Maliakkal B, Siddique A, Bhandari BR, Poordad F, Liu R, Lin CW, Ng T, Mensa FJ, Kort J. High svr4 rates achieved with the next generation ns3/4a protease inhibitor abt-493 and ns5a inhibitor abt-530 in non-cirrhotic treatment-naive and treatment-experienced patients with hcv genotype 3 infection (surveyor-2) Hepatology. 2015 Oct; 62:337A-8A.

170.

Pungpapong S, Leise MD, Watt KD, Vargas HE, Keaveny AP, Aqel BA. Multicenter experience using sofosbuvir/ledipasvir with or without ribavirin to treat hepatitis c genotype 1 relapsers after simeprevir and sofosbuvir treatment Hepatology. 2015 Oct; 62:716A.

RE-AIMS 7/22/2020 3:25:35 PM


171.

Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Biggins SW, Fallon MB, Tandon P, Subramanian RM, Maliakkal B, Thuluvath PJ, Vargas HE, Kamath PS, Thacker L, Bajaj JS. The association of non-selective beta-blocker use and acute kidney injury in patients with decompensated cirrhosis admitted into hospital - a study from the north american consortium for the study of end stage liver diseae (nacseld) Hepatology. 2015 Oct; 62:250A.

172.

Bajaj JS, Reddy KR, Garcia-Tsao G, Tandon P, Wong F, Biggins SW, Kamath PS, Fallon MB, Maliakkal B, Subramanian RM, Thuluvath PJ, Vargas HE, Thacker L, O'Leary JG. Wide variations in albumin use in hospitalized cirrhotic subjects: nacseld perspective Hepatology. 2015 Oct; 62:492A-3A.

173.

Wong F, O'Leary JG, Reddy KR, Garcia-Tsao G, Biggins SW, Vargas HE, et al. The association of non-selective beta-blocker use and acute kidney injury in patients with decompensated cirrhosis admitted into hospital - A Study from the North American Consortium for the Study of End Stage Liver Disease (NACSELD) AASLD The Liver Meeting, San Francisco, CA.2015 Nov;

174.

Bajaj JS, Reddy KR, Garcia-Tsao G, Tandon P, Wong F, Vargas HE, et al. Wide Variations in Albumin Use in Hospitalized Cirrhotic Subjects: NACSELD Perspective AASLD The Liver Meeting, San Francisco, CA.2015 Nov;

175.

Jacobson IM, Welzel TM, Vargas HE, Pedrosa MC, Terrault N, Dieterich D, et al. Efficacy, Change in MELD Score, and Safety by Baseline MELD Score in Patients with Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in the Phase 3 TURQUOISE-II Trial AASLD The Liver Meeting, San Francisco, CA.2105 Nov;

176.

Yang JD, Aqel BA, Watt KD, Vargas HE, Keaveny AP, Pungpapong S, et al. Hepatitis C and HCC Outcomes Among Patients Listed for Liver Transplant with HCV-HCC who Received Direct Acting Antiviral Therapy AASLD The Liver Meeting, San Francisco, CA.2015 Nov;

177.

Leise MD, Watt KD, Vargas HE, Keaveny AP, Aqel BA. Multicenter experience using Sofosbuvir/Ledipasvir with or without Ribavirin to treat hepatitis C genotype 1 relapsers after Simeprevir and Sofosbuvir Treatment. AASLD The Liver Meeting, San Francisco, California, Abstract 1038.2015 Nov 15;

178.

Kwo PY, Bennett M, Wang S, Vargas HE, Wyles DL, Overcash JS, et al. High SVR4 Rates Achieved with the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Naive and Treatment-Experienced Patients with HCV Genotype 3 Infection (SURVEYOR-2) AASLD The Liver Meeting, San Francisco, CA.2015 Nov;

179.

Mullhaupt B, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Yoshida EM, Lilly L, Willems B, Vargas H, Kumar P, Brown RS, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M. High efficacy of ledipasvir/sofosbuvir plus ribavirin among patients with decompensated cirrhosis who underwent liver transplant during participation in the solar-1 and-2 studies Journal Of Hepatology. 2016; 64:S749.

180.

Bajaj JS, Reddy K, Tandon P, Garcia-Tsao G, Wong F, Kamath P, Biggins S, Fallon M, Maliakkal B, Thuluvath P, Subramanian R, Vargas H, Lai J, Thacker L, O'leary J. In-hospital mortality related to hepatic encephalopathy is independent of acute-on-chronic liver failure and varies significantly across north america: nacseld experience Journal Of Hepatology. 2016; 64:S264.

181.

Vucicevic D, Kransdorf EP, Steidley DE, Vargas HE, Carey EJ. Vibration controlled transient elastography for identification of hepatic fibrosis in patients evaluated for cardiac transplantation or left ventricular assist device: a pilot study Journal Of Heart And Lung Transplantation. 2016 Apr; 35: (4)S210.

182.

Bajaj JS, Banerjee D, O'Leary JG, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, Biggins SW, Maliakkal B, Fallon MB, Lai JC, Thuluvath PJ, Subramanian RM, Vargas HE, Thacker L, Reddy KR. Drug resistant infections in hospitalized patients with cirrhosis are nosocomial and associated with renal and respiratory failure: results from nacseld Hepatology. 2016 Oct; 64: (1 Suppl)1019A-20A.

183.

Wong F, Reddy KR, O'Leary JG, Tandon P, Garcia-Tsao G, Kamath PS, Biggins SW, Maliakkal B, Fallon MB, Lai JC, Thuluvath PJ, Subramanian RM, Vargas HE, Thacker L, Bajaj JS. Predictive factors for the development of acute-onchronic liver failure in hospitalized decompensated cirrhotic patients Hepatology. 2016 Oct; 64: (1 Suppl)26A.

RE-AIMS 7/22/2020 3:25:35 PM


184.

Mousa O, Aqel BA, Leise MD, Yao JD, Watt K, Vargas HE, Keavenyl AP, Pungpapong S. Prevalence and factors associated with genotypic resistance-associated variants of hcv genotype 1 in ledipasvir/sofosbuvir relapsers - a multicenter study Hepatology. 2016 Oct; 64: (1 Suppl)971A.

185.

Bajaj JS, Reddy KR, O'Leary JG, Tandon P, Garcia-Tsao G, Wong F, Biggins SW, Fallon MB, Maliakkal B, Lai JC, Thuluvath PJ, Subramanian RM, Vargas HE, Thacker L, Kamath PS. Which extra-hepatic organ fails first does not affect mortality rates in cirrhotic inpatients Hepatology. 2016 Oct; 64: (1 Suppl)1015A-6A.

186.

Bajaj JSS, O'leary J, Wong F, Garcia-Tsao G, Tandon P, Biggins S, Kamath S, Lai J, Fallon M, Subramanian R, Maliakkal B, Thuluvath P, Vargas H, Thacker L, Reddy R. Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients Journal Of Hepatology. 2017; 66: (1)S378.

187.

Foster GR, Gane E, Asatryan A, Asselah T, Ruane PJ, Pol S, Poordad F, Stedman CA, Dore G, Roberts SK, Kaita K, Vierling J, Vargas HE, Kort J, Lin CW, Liu R, Ng T, Mensa F. Endurance-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive hcv genotype 3-infected patients without cirrhosis Journal Of Hepatology. 2017; 66: (1)S33.

188.

Dufour JF, Zuckerman E, Zadeikis N, Hezode C, Paik SW, Andreone P, Weiland O, Slim J, Flamm SL, Morgan T, Vargas H, Strasser S, Brown A, Yu Y, Porcalla A, Mensa F. Safety of glecaprevir/pibrentasvir in adults with chronic genotype 1-6 hepatitis c virus infection: an integrated analysis Journal Of Hepatology. 2017; 66: (1)S515.

189.

Bajaj JS, Tandon P, O'Leary JG, Biggins SW, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal BJ, Lai JC, Fallon MB, Thuluvath PJ, Subramanian R, Vargas HE, Thacker L, Reddy KR. Albumin treatment is associated with hyponatremia correction in large multi-center cirrhotic inpatient cohort Hepatology. 2017 Oct; 66 (S1):947A-8A

190.

Bajaj JS, Vargas HE, Reddy KR, Lai JC, O'Leary JG, Tandon P, Wong F, Ganapathy D, Mitrani R, Kelly M, Myer DM, Fagan A, Kalainy S, Sikaroodi M, Gillevet PM. Altered gut microbiota at hospitalization are associated with aclf, type of organ failure, and death in a multi-center North American cohort Hepatology. 2017 Oct; 66 (S1):445A-6A

191.

Wong F, Reddy KR, O'Leary JG, Tandon P, Biggins SW, Garcia-Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Chronic kidney disease in cirrhosis: patient characteristics and its effects on patient outcomes Hepatology. 2017 Oct; 66 (S1):948A-9A

192.

Chascsa DM, Mousa OY, Pungpapong S, Zhang N, Chervenak AE, Nidamanuri S, Rodriguez E, Franco D, Ryland K, Keaveny AP, Huskey J, Vargas HE, Aqel BA. Impact of hcv treatment before vs. after renal transplantation on time from listing to transplantation: a multi-center study Hepatology. 2017 Oct; 66 (S1):114A

193.

Bajaj JS, Reddy KR, Tan-Don P, Wong F, Kamath PS, Biggins SW, Fallon MB, Maliakkal BJ, Garcia-Tsao G, Lai JC, Thuluvath PJ, Subramanian R, Vargas HE, Thacker L, O'Leary JG. Prediction of fungal infection development and their impact on survival using the nacseld cohort Hepatology. 2017 Oct; 66 (S1):137A-8A

194.

Chascsa DM, Mousa OY, Pungpapong S, Zhang N, Chervenak A, Nidamanuri S, Rodriguez E, Franco D, Keaveny AP, Huskey JL, Vargas HE, Aqel BA. Impact of HCV Treatment before vs. after Renal Transplantation on Time from Listing to Transplantation: A Multi-Center Study. American Association for Study of Liver Disease (AASLD) Scientific Meeting, Washington DC. 2017 Nov.

195.

Bajaj JS, Tandon P, O'leary J, Wong F, Biggins S, Garcia-Tsao G, Kamath P, Maliakkal B, Fallon M, Thuluvath PJ, Lai J, Subramanian R, Vargas HE, Thacker L, Reddy R. Primary spontaneous bacterial peritonitis prophylaxis is associated with greater icu admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis Journal Of Hepatology. 2018 Apr; 68:S66

196.

Reddy KR, Tandon P, O'Leary JG, Wong F, Garcia-Tsao G, Kamath PS, Lai JC, Biggins SW, Thuluvath PJ, Fallon MB, Vargas HE, Subramanian RM, Thacker LR, Bajaj JS. Frequency and impact of clostridium difficile infection (cdi) in hospitalized patients with cirrhosis Hepatology. 2018 Oct; 68:1336A-7A

197.

Jacqueline G, Bajaj JS, Tandon P, Biggins SW, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal BJ, Lai JC, Fallon MB, Vargas HE, Thuluvath PJ, Subramanian RM, Thacker LR, Reddy KR. Liver transplantation (lt) after acute on chronic liver failure (aclf): the prospective multicenter nacseld experience Hepatology. 2018 Oct; 68:709A-10A

RE-AIMS 7/22/2020 3:25:35 PM


198.

Bajaj JS, Tandon P, O'Leary JG, Wong F, Garcia-Tsao G, Kamath PS, Biggins SW, Lai JC, Vargas HE, Maliakkal BJ, Fallon MB, Thuluvath PJ, Subramanian RM, Thacker LR, Reddy KR. Nosocomial infections negatively impact outcomes in cirrhotic inpatients and cannot be reliably predicted on admission Hepatology. 2018 Oct; 68:173A-4A

199.

Rodriguez EA, Perez RM, Zhang N, Lim ES, Miller CR, Schwartz MA, McGirr AJ, Srinivasan A, Hewitt WR, Silva AC, Rakela J, Vargas HE. Clinical impact of spontaenous portosystemic shunts on the short term outcome of liver transplantation American Journal Of Transplantation. 2019 Apr; 19:863. Epub 1900 Jan 01.

200.

Tse CS, Yang JD, Mousa O, Pungpapong S, Keaveny A, Nelson K, Aqel B, Dickson R, Vargas HE, Gores G, Roberts L, Leise M. Direct-acting antiviral agents are not associated with an increased risk of hepatocellular carcinoma recurrence in liver transplant recipients with hepatitis c Journal Of Hepatology. 2019 Apr; 70(1 Suppl):E571

201.

Bajaj JS, Tandon P, O'leary J, Wong F, Garcia-Tsao G, Biggins S, Kamath PS, Thuluvath PJ, Lai J, Vargas HE, Subramanian R, Maliakkal B, Fallon M, Thacker L, Reddy R. Potentially preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort Journal Of Hepatology. 2019 Apr; 70(1 Suppl):E630-1

202.

Wong F, Reddy R, Tandon P, O'leary J, Garcia-Tsao G, Lai J, Vargas HE, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation Journal Of Hepatology. 2019 Apr; 70(1 Suppl):E691-2

203.

Wong F, Pappas S, Vargas HE, Frederick T, Sanyal A, Jamil K. The diagnosis of hepatorenal syndrome: how much does use of the 2015 revised consensus recommendations affect earlier treatment and serum creatinine at treatment start? Journal Of Hepatology. 2019 Apr; 70(1 Suppl):E692-3

204.

Wong F, Reddy R, Tandon P, O'leary J, Garcia-Tsao G, Lai J, Vargas HE, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath PJ, Kamath PS, Thacker L, Bajaj JS. The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites Journal Of Hepatology. 2019 Apr; 70(1 Suppl):E692

205.

O'leary J, Reddy R, Tandon P, Biggins S, Wong F, Garcia-Tsao G, Kamath PS, Maliakkal B, Lai J, Fallon M, Thuluvath PJ, Subramanian R, Vargas HE, Thacker L, Bajaj J. Underutilization of hospice in inpatients with cirrhosis: the nacseld experience Journal Of Hepatology. 2019 Apr; 70(1 Suppl):E669

206.

Laique S, Zhang N, Hewitt WR, Bajaj JS, Vargas HE. Increased access to liver transplantation for patients with acute on chronic liver failure after implementation of share 35 rule: an analysis from the unos database Hepatology. 2019 Oct; 70(Suppl 1):1A

207.

Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai JC, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal BJ, Subramanian RM, Thacker L, Reddy KR. Insurance status is associated with inpatient and 90-day outcomes in a large hospitalized cohort of patients with cirrhosis Hepatology. 2019 Oct; 70(Suppl 1):653A-4A

208.

Bajaj JS, Xie J, Kelly M, Duarte-Rojo A, Acharya C, Wade J, Flud C, White M, Fagan A, de Sicilia MGS, Thacker L, Vargas HE. Interaction of pre-dementia mild cognitive impairment and hepatic encephalopathy in elderly patients with cirrhosis: a multi-center study Hepatology. 2019 Oct; 70(Suppl 1):37A-8A

209.

Pollock JR, Haglin JM, Vargas HE. 20 years of medicare reimbursement trends in transplant surgery Journal Of Investigative Medicine. 2020 Jan; 68(Suppl 1):A83

RE-AIMS 7/22/2020 3:25:35 PM


Ask Mayo Expert Model

1. Sanchez W, Aqel BA, Arora AS, Berbari EF, Byrne TJ, Carey EJ, Chervenak AE, Edson RS, Harnois DM, Keaveny AP, Loftus CG, Oxentenko AS, Poterucha JJ, Pungpapong S, Rakela J, Rizza SA, Rosen CB, Rosser BG Jr., Sampathkumar P, Sohail MR, Sweetser SR, Vargas HE, Vege S, Virk A, Walker RC, Wilhelm MP, Greenlund AC, Linderbaum JA. Hepatitis B AskMayoExpert.2014;

2. Aqel BA, Sanchez W, Arora AS, Berbari EF, Byrne TJ, Carey EJ, Chervenak AE, Edson RS, Harnois DM, Keaveny AP, Loftus CG, Oxentenko AS, Poterucha JJ, Pungpapong S, Rizza SA, Rosen CB, Rosser BG Jr., Sampathkumar P, Sohail MR, Sweetser SR, Vargas HE, Vege S, Virk A, Walker RC, Wilhelm MP, Greenlund AC, Linderbaum JA. Hepatitis B AskMayoExpert.2014;

3. Keaveny AP, Vargas HE. Hepatitis C (adult) In: AskMayoExpert. 03-28-2016. Available from: http://askmayoexpert.mayoclinic.org

* Indicates that the primary author was a mentee of this author.

Miscellaneous

1. Talley NJ, Lindor KD, Vargas HE. Preface. 2010:XI.

Letters

1. Gallegos-Orozco JF, Werner KT, Rosati M, Byrne TJ, Balan V, Vargas HE, Rakela J. Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy. Am J Gastroenterol. 2008 Aug; 103(8):2161-2. PMID:18796126 DOI:10.1111/j.1572-0241.2008.01982_18.x

2. Singh V, Rudraraju M, Carey EJ, Byrne TJ, Vargas HE, Williams JE, Balan V, Douglas DD, Rakela J. Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement. J Clin Gastroenterol 2009 Mar; 43 (3):287 PMID:18813027 DOI:10.1097/MCG.0b013e31815a5796

3. Adike A, Smith ML, Chervenak A, Vargas HE. Hydroxycut-related Vanishing Bile Duct Syndrome. Clin Gastroenterol Hepatol. 2017 Jan; 15 (1):142-144 Epub 2016 May 02 PMID:27151488 DOI:10.1016/j.cgh.2016.04.028

RE-AIMS 7/22/2020 3:25:35 PM


curriculum vitae and bibliography hugo e vargas, md...11/2016 re-aims 7/22/2020 3:25:34 pm hugo e...

Documents